Robert P. Friedland, MD

PUBLICATIONS

PAPERS PUBLISHED IN REFEREED JOURNALS

1.      Friedland RP, Yahr MD.  Meningoencephalopathy secondary to infectious mononucleosis.  Archives of Neurology 34:186-188, 1977.

2.      Friedland RP, Whetsell W.  Clinicopathologic notes: Adrenocortical carcinoma with Cushing's syndrome, organic psychosis and aphasia, Mount Sinai Journal of Medicine 45:509-523, 1978.

3.      Friedland RP, Grant S.  Hematocrit, viscosity and cerebral blood flow.  American Heart Journal 97:404-405, 1979.

4.      Yen CK, Yano Y, Budinger TF, Friedland RP, Derenzo SE, Huesman RH, O'Brien HA.  Brain tumor evaluation using RB-82 and positron emission tomography.  Journal of Nuclear Medicine 23:532-537, 1982.

5.      Cooper JA, Nakada T, Knight RT, Friedland RP.  Autosomal dominant motor system degeneration in a black family.  Annals of Neurology 14:585-587, 1983.

6.      Friedland RP, Budinger TF, Yano Y, Huseman R, Knittel B, Derenzo, SE, Koss, B, Ober BA.  Regional cerebral metabolic alterations in Alzheimer-type dementia:  Kinetic studies with 18-fluorodeoxyglucose.  Journal of Cerebral Blood Flow and Metabolism 3, Suppl 1:S510-511, 1983.

7.      Friedland RP, Mathis CA, Budinger TF, Moyer BR.  Labeled choline and phosphorylcholine:  Body distribution and brain autoradiography.  Journal of Nuclear Medicine 24:812-815, 1983.

8.      Friedland, RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman R, Derenzo S.  Regional cerebral metabolic alterations in dementia of the Alzheimer-type: positron emission tomography with 18-fluorodeoxyglucose.  Journal of Computer Assisted Tomography 7:590-598, 1983.

9.      Jones A, Friedland RP, Koss B, Ober BA, Stark, L.  Saccadic intrusions in Alzheimer-type dementia.  Journal of Neurology 229:189-194, 1983.

10.     Friedland RP, Yano Y, Budinger TF, Ganz E, Huesman RH, Derenzo SE, Knittel B.  Quantitative evaluation of blood brain barrier integrity in Alzheimer-type dementia:  Positron emission tomographic studies with rubidium-82.  European Neurology 22, Suppl 2:19-20, 1983.

11.     Koss E, Ober BA, Delis D, Friedland RP.  The Stroop color-word test: Indicator of dementia severity.  International Journal of Neurosciences 24:53-61, 1984.

12.     Friedland RP, Prusiner S, Jagust W, Budinger TF.  Bitemporal hypometabolism in Creutzfeldt-Jakob disease:  Positron emission tomography with 18F-2-fluorodeoxyglucose.  Journal of Computer Assisted Tomography 8:978-981, 1984.

13.     Friedland RP, Budinger TF, Brant-Zawadzki MN, Jagust WJ.  The diagnosis of Alzheimer-type dementia:  a preliminary comparison of PET and proton NMR imaging.  Journal of the American Medical Association 252:2750-2752, 1984.

14.     Friedland RP, Budinger TF, Koss E, Ober BA.  Alzheimer's disease:  anterior-posterior and lateral hemispheric alterations in cortical glucose utilization.  Neuroscience Letters 53:235-240, 1985.

15.     Ober BA, Koss E, Friedland RP, Delis DC.  Processes of verbal memory failure in Alzheimer-type dementia.  Brain and Cognition 4:90-103, 1985.

16.     Jagust WJ, Friedland RP, Budinger TF.  Positron emission tomography differentiates normal pressure hydrocephalus from Alzheimer's disease.  Journal of Neurology, Neurosurgery and Psychiatry 48:1091-1096, 1985.

17.     Koss E, Friedland RP, Ober BA, Jagust WJ. Differences in lateral hemispheric asymmetries of glucose utilization between early-and late-onset Alzheimer-type dementia.  American Journal of Psychiatry 142:638-640, 1985.

18.     Jagust WJ, Friedland RP.  Positron emission tomography in the study of Alzheimer's disease.  VA Practitioner 2:55-66, 1985.

19.     Friedland RP, Koss E, Jagust WJ.  Lateral hemispheric asymmetries of glucose use in Alzheimer's disease:  Relationships to behavior, age of onset and prognosis.  Journal of Cerebral Blood Flow and Metabolism 5, (Suppl 1):S123-124, 1985.

top

20.     Friedland RP, Jagust WJ, Budinger TF, Huesman RH, Knittel B.  Methodological factors affecting the accuracy of metabolic measurements in PET studies with (18F)-2-fluoro-2-deoxy-D-glucose (FDG).  Journal of Cerebral Blood Flow and Metabolism 5(Suppl. 1):S609-610, 1985.

21.     Ober BA, Dronkers NF, Koss E, Friedland RP, Delis DC.  Retrieval from semantic memory in Alzheimer-type dementia.  Journal of Clinical and Experimental Neuropsychology 8:75-92, 1986.

22.     Lakshminarayanan V, Friedland RP, Muller EC, Koss E, Stark L.  The vestibular-ocular reflex in Alzheimer's disease.  Neuro-ophthalmology 6:205-208, 1986.

23.     Jagust WJ, Budinger TF, Huesman RH, Friedland RP, Mazoyer BM, Knittel BL.  Methodological factors affecting PET measurements of cerebral glucose metabolism.  Journal of Nuclear Medicine 27:1358-1361, 1986.

24.     Luxenberg J, Friedland RP, Rapoport SI.  Quantitative X-ray computed tomography (CT) in dementia of the Alzheimer type (DAT).  Canadian Journal of the Neurological Sciences 13:570-572, 1986.

25.     Haxby JV, Grady CL, Friedland RP, Rapoport SI.  Neocortical metabolic abnormalities precede nonmemory cognitive impairments in early dementia of the Alzheimer type:  Longitudinal confirmation.  Journal of Neural Transmission 24:49-53, 1987.

26.     Grady C, Haxby JV, Horwitz B, Sundaram M, Berg G, Schapiro M, Friedland RP, Rapoport SI.  A longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type.  Journal of Clinical and Experimental Neuropsychology 10:576-596, 1988.

27.     Kaye JA, May C, Daly E, Atack JR, Sweeney DJ, Luxenberg JS, Kay AD, Kaufman S, Milstein S, Friedland RP, Rapoport SI.  Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features.  Neurology 38:554-557, 1988.

28.     Rainero I, May C, Kaye JA, Friedland RP, Rapoport SI.  Cerebrospinal fluid alpha melanocyte stimulating hormone in dementia of the Alzheimer type.  Neurology 38:1281-1284, 1988.

29.     Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B.  Longitudinal studies of regional cerebral glucose utilization in Alzheimer's disease.  Neurology 38:909-912, 1988.

30.     Luxenberg J, Plato CC, Fox KM, Friedland RP, Rapoport SI.  Digital and palmar dermatoglyphics in dementia of the Alzheimer's type.  Journal of Medical Genetics 30:733-740, 1988.

31.     Koss E, Weiffenbach JM, Haxby JV, Friedland RP.  Olfactory detection and identification performance in Alzheimer's disease.  Neurology 38:1228-1232, 1988.

32.     Friedland RP, Horwitz B, Koss E.  Measurement of disease progression in Alzheimer's disease.  Neurobiology of Aging 9:95-97, 1988.

33.     Luxenberg J, Swedo S, Flament MF, Friedland RP, Rapoport SI.  Neuroanatomic abnormalities in obsessive compulsive disorder detected with quantitative x-ray computed tomography.  American Journal of Psychiatry 145: 1089-1093, 1988.

34.     Friedland RP, Koss E, Haxby JV, Grady C, Luxenberg J, Schapiro MB,  Kaye J. The clinical and biological heterogeneity of Alzheimer's disease.  Annals of Internal Medicine 109:298-311, 1988.

35.     Friedland RP, Koss E, Kumar A, Gaine S, Metzler D, Haxby JV, Moore A,  Rapoport SI, Motor vehicle crashes in dementia of the Alzheimer type.  Annals of Neurology 24:782-786, 1988.

36.     Kumar A, Koss E, Metzler D, Moore A, Friedland RP.  Behavioral symptomatology in dementia of the Alzheimer type.  Alzheimer's Disease and Associated Disorders: An International Journal 2:363-365, 1988.

37.     Rainero I, Kaye JA, May C, Durso R, Katz DI, Albert ML, Wolfe N, Pinessi L, Friedland RP, Rapoport SI. Alpha-melanocyte stimulating hormone immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease.  Archives of Neurology 45:1224-1227, 1988.

38.     Haxby JV, Grady CL, Koss E, Horwitz B, Shapiro M, Friedland RP, Rapoport SI.  Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type.  Neurology 38:1853-1863, 1988.

39.     Kaye JA, May C, Atack JR, Daly E, Sweeney DL, Beal MF, Kaufman S, Milstein S, Friedland RP, Rapoport SI.  Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease.  Annals of Neurology 24:647-650, 1988.

40.     Friedland RP.  Positron imaging in the dementing illnesses.  Journal of Neuropsychiatry and Clinical Neurosciences 39:309-310, 1989.

41.     Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland RP, Rapoport SI, Rapoport JL.  Cerebral glucose metabolism in childhood-onset obsessive compulsive disorder.  Archives of General Psychiatry 46:518-523, 1989.

42.     Friedland RP, Jagust WJ, Huesman RH, Koss E, Knittel B, Mathis CA, Ober BA, Mazoyer BM, Budinger TF.  Regional cerebral glucose transport and utilization in Alzheimer's disease.  Neurology 39:1427-1434, 1989.

43.     Friedland RP. "Normal" pressure hydrocephalus and the saga of the treatable dementias.  Journal of the American Medical Association 262:2577-2581, 1989.

44.     Grady CL, Berg G, Carson RE, Daube-Witherspoon WE, Friedland RP, Rapoport SI. Quantitative comparison of glucose metabolic rates from two position emission tomographs.  Journal of Nuclear Medicine 30:1386-1392, 1989.

45.     Schapiro MB, Luxemberg JS, Kaye JA, Haxby JV, Friedland RP, Rapoport SI. Serial quantitative CT analysis of brain morphometrics in adult Down's Syndrome at different ages.  Neurology 39:1349-1353, 1989.

46.     Friedland RP.  Position emission tomography in dementia.  Seminars in Neurology 9:338-344, 1989.

47.     Friedland RP, May C, Dahlberg J. The viral hypothesis of Alzheimer's Disease: Absence of antibodies to lentiviruses.  Archives of Neurology 47:177-178, 1990.

48.     Ship JA, DeCarli C, Friedland RP, Baum B. Diminished submandibular salivary flow in dementia of the Alzheimer type.  Journal of Gerontology 45:M61-66, 1990.

49.     May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI.  Cerebrospinal fluid production is reduced in healthy aging.  Neurology 40:500-503, 1990.

top

50.     Friedland RP, Luxenberg JS, Koss E. A quantitative study of intracranial calcification in dementia of the Alzheimer type.  International Psychogeriatrics 2:37-43, 1990.

51.     Kaye JA, Grady CL, Haxby JV, Moore A, Friedland RP. Plasticity in the aging brain: Reversibility of anatomic, metabolic and cognitive deficits in normal pressure hydrocephalus following shunt surgery.  Archives of Neurology 47:1336-1341, 1990.

52.     Schapiro MB, Grady CL, Kumar A, Herscovitch P, Haxby JV, Moore AM, White B, Friedland RP, Rapoport SI. Regional cerebral glucose metabolism is normal in young adults with Down Syndrome.  Journal of Cerebral Blood Flow and Metabolism 10:199-206, 1990.

53.     May C, Haber M, Young SH, Tomai TP, Csako G, Friedland RP. Osmoregulation in Alzheimer's Disease.  Dementia 1:90-94, 1990.

54.     Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, Friedland RP, Rapoport SI. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Archives of Neurology 47:753-760, 1990.

55.     Schapiro MB, Kumar A, White B, Fox D, Grady CL, Haxby JV, Friedland RP, Rapoport SI.  Dementia without mental retardation in mosaic translocation Down Syndrome.  Brain Dysfunction 3:165-174, 1990.

56.     Kumar A, Schapiro MB, Haxby JV, Grady CL, Friedland RP.  Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features.  Journal of Psychiatric Research 24(2):97-109, 1990.

57.     Kumar A, Schapiro MB, Grady CL, Haxby JV, Wagner E, Salerno JA, Friedland RP, Rapoport SI. High resolution studies of cerebral glucose metabolism in Alzheimer's disease.  Neuropsychopharmacology 4:35-46, 1991.

58.     Friedland RP, Iadecola C. Roy and Sherrington (1890): A centennial re-examination of "On the regulation of the blood-supply of the brain".  Neurology 41:10-14, 1991. (Recipient of Lawrence McHenry Award, American Academy of Neurology, 1990)

59.     Koss E, Haxby JV, DeCarli C, Schapiro MB, Friedland RP, Rapoport SI. Patterns of performance preservation and loss in healthy aging.  Developmental Neuropsychology 7:99-113, 1991.

60.     Ober BA, Jagust WJ, Koss E, Delis DC, Friedland RP. Visuoconstructive performance and regional cerebral glucose metabolism in Alzheimer's disease.  Journal of Clinical and Experimental Neuropsychology 13:752-772, 1991.

61.     DeCarli C, Fugate L, Falloon J, Eddy J, Katz D, Friedland R, Rapoport S, Brouwers P, Pizzo P.  Brain growth and cognitive improvement in children with HIV-induced encephalopathy after six months of continuous infusion AZT therapy.  Journal of the Acquired Immune Deficiency Syndrome 4:585-592, 1991.

62.     Godec MS, Asher DM, Masters CL, Kozachuk WE, Friedland RP, Gibbs CJ, Gajdusek DC, Rapoport SI, Schapiro MB.  Evidence against the transmissibility of Alzheimer's Disease.  Neurology 41:1320, 1991.

63.     Majocha RE, Reno JM, Friedland RP, Van Haight C, Lyle LR, Marotta CA.  Development of a monoclonal antibody specific for ß/A4 Amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy Journal of Nuclear Medicine 33:2184-2189, 1992.

64.     Friedland RP.  Alzheimer's disease:  Clinical features and differential diagnosis Neurology 43 (suppl 4):S45-S51, 1993.

65.     Friedland RP, Koss E, Lerner A, Hedera P, Jagust WJ, Ellis W, Dronkers N, Ober A.  Functional imaging, the frontal lobes, and dementia.  Dementia 4:192-203, 1993.  (Abstracted in NeuroCase 4:8, 1998)

66.     Lerner A, Friedland RP, Whitehouse PJ.  Editorial:  Role of biological markers of Alzheimer's Disease.  Alzheimer's Disease:  An International Journal 6:197-200, 1993.

67.     Friedland RP, Lerner AJ, Hedera P, Brass EP, Encephalopathy associated with bismuth subgallate therapy.  Clinical Neuropharmacology 16:173-176, 1993.

68.     Drachman DA, Swearer JM, Barnes HJ, Woodward BM, Peterson KE, Moonis M, Weintraub S, Morecroft K, Guinessey J, Acar D, Sandson T, Blass J, Nolan K, Ryan B, Morris JC, Ball LA, Friedland RP, Martin R, DeKosky ST, FuQua-Whitley D, Lineman DA, Castle J.  Driving and Alzheimer's Disease:  The risk of crashes.  Neurology 43:2448-2456, 1993.

69.     Lai S, Hopkins AL, Haacke EM, Li D, Wasserman BA, Buckley P, Friedman L, Meltzer H, Hedera P, Friedland RP.  Identification of vascular structures as a major source of signal contrast in high resolution 2D and 3D functional activation imaging of the motor cortex at 1.5T:  Preliminary results.  Magnetic Resonance in Medicine 30:387-392, 1993.

70.     Hedera P, Friedland RP.  Duane's syndrome with giant aneurysm of the vertebral basilar arterial junction.  Journal of Clinical Neuro-ophthalmology 13:271-274, 1993.

71.     Friedland RP.  Editorial:  Epidemiology, education, and the ecology of Alzheimer's disease.  Neurology 43:246-249, 1993 (published also in Portuguese in : Cadernos IPUB Envelhecimento e Saude Mental, Ed. By A. Leibing, Instituto de Psiquiatria, UFRJ, No. 10, 1999, pp. 165-174.

72.     Friedland RP.  Epidemiology and the multiple determinants of Alzheimer's disease.  Neurobiology of Aging 15:239-241, 1994.

73.     Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA.  Development of an anti-Aß monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease.  Molecular Neurobiology 9:107-113, 1994.

74.     Lerner AJ, Koss E, Patterson MB, Hedera P, Ownby RL, Friedland RP, Whitehouse PJ.  Concomitants of visual hallucinations in Alzheimer's disease.  Neurology 44:523-527, 1994.

75.     Hedera P, Cohen ML, Lerner AJ, Friedland RP.  Dementia preceding motor symptoms in Parkinson's disease:  A case study.  Neuropsychiatry, Neuropsychology and Behavioral Neurology 7:67-72, 1994.

76.     Weinstein EA, Friedland RP, Wagner EE. Denial/unawareness of impairment and symbolic behavior in Alzheimer's disease. Neuropsychiatry, Neuropsychology and Behavioral Neurology 7:176-184, 1994.

77.     Hedera P, Lai S, Haacke EM, Lerner AJ, Hopkins AL, Lewin JS, Friedland RP. Abnormal connectivity of the visual pathways in human albinos demonstrated by susceptibility sensitized magnetic resonance imaging. Neurology 44:1921-1926, 1994.

78.     Haacke EM, Hopkins A, Lai S, Buckley P, Friedman L, Meltzer H, Hedera P, Friedland RP, Klein S, Thompson L, Detterman D, Tkach J, Lewin JS.  2D and 3D high resolution gradient echo functional imaging of the brain venous contributions to signal in motor cortex studies.  NMR in Biomedicine 7:54-62, 1994.

79.     Hedera P, Lerner AJ, Castellani R, Friedland RP.  Concurrence of Alzheimer's disease, Parkinson's disease; diffuse Lewy body disease and amyotrophic lateral sclerosis.  Journal of Neurological Sciences 128:219-224, 1995.

80.     Hedera P, Wu D, Lewin JS, Miller D, Lerner AJ, Friedland RP.  Temporal patterns of uncoupling between oxidative metabolism and regional cerebral blood flow demonstrated by functional magnetic resonance imaging.  Investigative Radiology 30:625-633, 1995.

81.     Premkumar DRD, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.  American Journal of Pathology 148:2083-95, 1996.

82.     Hedera P, Lai S, Lewin JS, Haacke EM, Wu D, Lerner AJ, Friedland RP.  Assessment of cerebral blood flow reserve using functional magnetic resonance imaging.  Journal of Magnetic Resonance Imaging 6:718-725, 1996.

83.     Thal LF, Carta A, Clarke WR, Ferris SH, Friedland RP, et al.  A one-year multicenter placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer’s disease.  Neurology 47:705-711, 1996.

84.     Ogeng’o JA, Cohen DL, Sayi G, Matuja WB, Chande HM, Kitinya J, Kimani JK, Friedland RP, Mori H, Kalaria RN.  Cerebral amyloid ß protein deposits and other alzheimer lesions in non-demented elderly East Africans.  Brain Pathology 6:101-107, 1996.

top

85.     Salomon A, Jao S-C, Marcinowski K, Friedland RP, Zagorski M. Nicotine inhibits amyloid formation by the ß-peptide. Biochemistry 35:13568-78, 1996.

86.     Ford AB, Mefrouche Z, Friedland RP, Debanne SM.  Smoking and cognitive impairment: A population based study.  Journal of the American Geriatrics Society 44:905-909,1996.

87.     Lewin JS, Friedman L, Wu D, Miller D, Thompson L, Klein S, Wise A, Hedera P, Buckley P, Friedland RP. Cortical localization of human sustained attention: Detection with functional MR using a visual vigilance paradigm. Journal of Computer Assisted Tomography 20:695-701, 1996.

88.     Lundberg C, Johansson K, Ball K, Bjerre B, Blomqvist C, Braekhus A, Brouwer W, Bylsma F, Carr D, Englund L, Friedland RP, et al.  Dementia and driving - an attempt at consensus.  Alzheimer’s Disease and Associated Disorders 11:28-37, 1997.

89.     Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP. Delirium in Alzheimer’s disease. Alzheimer’s Disease and Associated Disorders 11:16-20, 1997.

90.     Friedland RP. Strategies for driving cessation in Alzheimer’s disease. Alzheimer’s Disease and Associated Disorders 11:73-75, 1997.

91.     Hedera P, Friedland RP. Cerebral autosomal dominant anteriopathy with subcortical infarcts and leukoencephalopathy: Study of two American families with predominant dementia. Journal of Neurological Sciences 146:27-33, 1997.

92.     Lerner AJ, Koss E, Debanne SM, Rowland DY, Smyth KA, Friedland RP. Interactions of smoking history with estrogen replacement therapy as protective factors for Alzheimer’s disease (Letter). Lancet 349:403-404, 1997.

93.     Kalaria RN, Ogeng’o JA, Patel NB, Sayi JG, Kitinya JN, Chande HM, Matuja WB, Mtui EP, Kimani JK, Premkumar DRD, Koss E, Gatere S, Friedland RP.  Evaluation of risk factors for Alzheimer’s disease in elderly east Africans, Brain Research Bulletin 44:573-577, 1997.

94.     Sayi JG, Patel NB, Premkumar DRD, Adem A, Winblad B, Matuja WB, Mtui EP, Gatere S, Friedland RP, Koss E, Kalaria RN. Apolipoprotein E polymorphism in elderly East Africans. East African Medical Journal 74:668-670, 1997.

95.     Hedera P, Wu D, Collins S, Lewin JS, Miller D, Lerner AJ, Klein S, Friedland RP.  Sex and EEG synchronization after photic stimulation predict signal changes in the visual cortex detected on functional MR images.  American Journal of Neuroradiology, 19:853-857, 1998.

96.     Perry G, Smith MA, McCann CE, Siedlak SL, Jones P, Friedland RP. Cerebrovascular muscle atrophy is a feature of Alzheimer Disease. Brain Research 791:63-66, 1998.

97.     Muzic RF, Berridge MS, Friedland RP, Zhu N, Nelson AD.  Quanitification of specific binding of [¹¹C] nicotine in human brain using PET.  Journal of Nuclear Medicine 39:2048-2054, 1998.

98.     Friedland RP, Farrer LA, Cupples LA, Debanne SM, Lerner AJ, and the MIRAGE Study Group.  Smoking and risk of Alzheimer’s disease (letter) Lancet 352:819, 1998.

99.     Friedland RP, McMonagle J. Medical Legal Aspects of Alzheimer’s disease. Journal of the Cleveland Bar Association 70:69, 1999.

100.   Shi J, Perry G, Aliev G, Smith MA, Ashe KH, Friedland RP.  Serum amyloid P is not present in amyloid ß deposits of a transgenic animal model. NeuroReport  10:3229-3232, 1999.

101.   Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: The insidious pathogenesis of Alzheimer’s disease.  Neurobiology of Aging 21:357-361, 2000.

102.   Aliev G, Shi J, Perry G, Friedland RP, LaManna J. Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet.  The Anatomical Record 259:1-10, 2000.

103.   Lerner AJ, Elston R, Chen C, Friedland RP. Response of the hypothalamic-pituitary-adrenal axis to lumbar puncture induced stress. Journal of Alzheimer’s Disease 2:193-198, 2000.

104.   Bowirrat A, Friedland, RP, Chapman J, Korczyn AD. Expedited publication:The very high prevalence of Alzheimer’s disease in an Arab population is not explained by high APOE e4 allele frequency. Neurology 55:731, 2000.

105.   Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxidative stress precedes amyloid-Beta deposition in Down’s syndrome. Journal of Neuropathology and Experimental Neurology 59:1011-1017,2000.

106.   Aliev, G, Smith, MA, Turmaine, M, Neal ML, Zimina, TV, Friedland, RP, Perry, G, LaManna, JC, Burnstock, G.  Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic Watanabe rabbits. Experimental and Molecular Pathology 71, 40-54, 2000

107.   Zeng H, Shao H, Menon NK, Yang J, Salomon AR, Friedland RP,  Zagorski M. Nicotine and amyloid formation. Biological Psychiatry 49:248-257, 2001.

108.   Demissie S, Green RC,  Mucci L, Tziavas S, Martelli K, Bang K, Coons L, Bourque S, Buchillon D, Johnson K,  Smith T, Lautenschlager N,  Friedland RP, Cupples LA, Farrer LA.  Reliability of information collected by proxy in family studies of Alzheimer’s disease.  Neuroepidemiology 20:105-111, 2001.

109.   Seyidova D, Aliev G, Neal ML, Shi J, Vigano T, Hernandez A, Folco G, Soas AH, Smith MA, Perry G, LaManna JC, Friedland RP.The effect of agonists and antagonists on the morphology of non-transformed human smooth muscle cells in vitro Journal of Submicroscopic Cytology and Pathology (in press).

110.   Bowirrat A, Treves TA, Friedland RP, Korczyn AD. Prevalence of Alzheimer’s type dementia in an elderly Arab population. European Neurology 8:119-123, 2001.

111.   Petot GJ, Debanne SM, Reidel TM,. Smyth KA, Cook TB, Koss E, Lerner AJ, Friedland RP. Surrogate responders do not introduce bias in a case control study of dietary risk factors for Alzheimer’s disease. Journal of the American Dietetic Association 102:848-850, 2002.

112.   Friedland RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, Petot GJ, Debanne SM. Patients with Alzheimer’s disease have reduced premorbid activities compared to healthy controls. Proceedings of the National Academy of Sciences (USA) 98:3440-3445, 2001.

113. Aliev, G, Seyidove, D, Neal, ML, Shi, J, Vigano, T, Hernandez, A, Folco, G., Soas, AH, Zimina, TV, Smith, MA, Perry, G, Lamanna, JC, Friedland, RP. The effect of agonists and antagonists on the morphology of non-transformed human smooth muscle cell in vitro. Journal of Submicroscopic Cytology and Pathology 33:141-149, 2001.

114.   Debanne SM, Petot GJ, Li J, Koss E, Lerner AJ, Riedel TM, Rowland DY, Smyth KA, Friedland RP. On the use of surrogate respondents for controls in a case-control study of Alzheimer’s disease. Journal of the American Geriatrics Society 49:1-5,2001.

115. Mizrahi E, Fritsch T, Smyth KA, Friedland RP, Lerner AJ. Medication use in Alzheimer’s Disease. Clinical Gerontologist (in press).

116. Aliev G, Smith MA, Zimina TV, Neal ML, Lamb BT, Nunomura A, Seyidova D, Vinters HV, LaManna JC, Perry G, Friedland RP. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer’s’ disease.  Brain Pathology 12:21-35, 2002.

117. Fritsch T, McLendon MJ, Smyth KA, Lerner AJ, Chen CH, Petot GJ, Debanne SM, Soas A, Friedland RP. Effects of educational attainment on the clinical expression of Alzheimer’s disease: Results from a research registry. American Journal of Alzheimer’s Disease and Other Dementias

16:369-376, 2001.

118. Mizrahi E, Jacobsen DW, Friedland RP. Plasma homocysteine: A new risk for Alzheimer’s disease? Israel Medical Association Journal 4:1-4,2002.

119. Friedland RP, Petot GJ, Farrer LF. Diet and Alzheimer’s disease. Arab Journal of Psychiatry 13:10-17, 2002.

120. Shi J, Perry G, Berridge MS, Aliev G, Siedlak SL, Smith MA, La Manna JC, Friedland RP. Labeling of cerebral Ab deposits in vivo using intranasal bFGF and SAP component in mice, Journal of Nuclear Medicine 43:1044-1051, 2002. (Invited Commentary on this paper was published in the same issue: Potential for a sprecific neuroradiological diagnosis of Alzheimer’s disease, Blass JB, Journal of Nuclear Medicine 43:1051-1053, 2002).

121. Aliev G, Smith MA, Perry G, Samedov S, Seyidova D, Friedland RP, La Manna JC, Gasimov EK. The experimental model of Alzheimer’s disease and its selective pharmacological treatments. Academy of Sciences of Azerbaijan Reports 57:112-118, 2001.

122. Friedland RP, Lipid Metabolism, epidemiology and the mechanisms of Alzheimer’s disease. Annals of the New York Academy of Sciences 977:387-390, 2002

123. Bowirrat A, Friedland RP, Farrer L, Baldwin C, Korczyn A.  Genetic and environmental risk factors for Alzheimer’s disease in Israeli Arabs. Journal of Molecular Neuroscience 19: 239-245, 2002.

124. Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, Winters HV, Head E, Perry G, Lamanna JC, Friedland RP, Cotman CW.  Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Annals of the New York Academy of Sciences 977:45-64, 2002.

125. Aliev G, Smith MA, Seyidova D, Neal ML, Shi J, Loizidou M, Turmaine M, Friedland RP, Taylor I, Burnstock G, Perry G, Lamanna JC. Increased expression of NOS and ET-1 immunoreactivity in human colorectal metastatic liver tumours is associated with selective depression of constitutive NOS immunoreactivity in vessel endothelium. J Submicroscopic and Cytological Pathology 34:37-50, 2002  

126. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, DeCarli C, Kukull W, Chui H, Edeki T, Griffith P, Friedland RP, Bachman D, Farrer LA: Depression as a risk factor for Alzheimer’s disease: The MIRAGE study. Archives of Neurology 60:753-759,2003.

127. Petot G, Chen C, Traore F, Debanne S, Friedland RP, Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. Metabolism 52:279-281, 2003.

128. Farrer, L.A., Friedland RP, Bowirrat A, Waraska, Korczyn AD, Baldwin CT. Genetic and environmental risk factors for Alzheimer’s disease in Israeli Arabs. Journal of Molecular Neuroscience 20:207-212, 2003.

129.  Farrer, LA, Bowirrat, A, Friedland RP, Waraska, K, Korczyn, AD, Baldwin, CT.  Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Human Molecular Genetics 12:415-422, 2003.

130. Mizrahi EH, Jacobsen DW, Debanne SM, Traore F, Lerner AJ, Friedland RP, Petot GJ. Plasma total homocysteine levels, dietary B6 and folate intake in AD and healthy aging. Journal of Nutrition, Health and Aging 7:160-165,2003.

131. Bowirrat A, Friedland RP, Korczyn AD, Vascular dementia among elderly Arabs in Wadi Ara, Journal of Neurological Sciences 203-204:73-76, 2003.

132. Friedland RP. Editorial: Fish consumption and the risk of Alzheimer’s disease: Is it time to make dietary recommendations? Archives of Neurology, 60:923-924, 2003.

133. Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, Friedland RP, LaManna JC, Smith MA, Perry G. Mitochondria and vascular lesions as a central target for the development of Alzheimer’s disease and Alzheimer-like pathology in transgenic mice. Neurological Research 25:655-674, 2003.

134. Castellani RJ, Smith MA, Perry G, Friedland RP. Cerebral amyloid angiopathy: Major contributor or decorative response to Alzheimer’s disease pathogenesis.  Neurobiology of Aging (in press).

135. Petot G, Frieldand RP. Diet, lipids and Alzheimer’s disease. Journal of the Neurological Sciences (in press).

top

 

BOOKS AND BOOK CHAPTERS

 

1.      Weinstein EA, Friedland RP (Editors): Advances in Neurology, Volume 18: Hemi- inattention and Hemisphere Specialization, Raven Press, New York, 1977.

2.      Friedland RP, Weinstein EA.  Hemi-inattention and hemisphere specialization: Introduction and historical review. In: Advances in Neurology, Volume 18: Hemi-inattention and Hemisphere Specialization. Edited by Weinstein EA, Friedland RP, Raven Press, New York, 1977, pp. 131.

3.      Weinstein EA, Friedland RP. Behavioral disorders associated with hemi-attention. In: Advances in Neurology, Volume 18: Hemi-inattention and hemisphere specialization, Edited by Weinstein EA, Friedland RP, Raven Press, New York, 1977, pp. 51-62.

4.      Weinstein EA, Friedland RP. Glossary and concluding remarks. In: Advances in Neurology, Volume 18, Hemi-inattention and hemisphere specialization, Edited by Weinstein EA, Friedland RP, Raven Press, New York, 1977, pp. 137-147.

5.      Friedland RP. (Editor): The Selected Papers of Morris B. Bender, Raven Press, New York, 445 pages, 1983.

6.      Budinger TF, Huesman RH, Knittel B, Friedland RP, Derenzo SE. Physiological modeling of dynamic measurements of metabolism using positron emission tomography. In: The Metabolism of the Human Brain Studied with Positron Emission Tomography. Edited by T. Greitz et al, Raven Press, New York, pp. 165-183, 1985.

7.      Friedland RP, Budinger TF, Jagust WJ, Yano Y, Huesman RH, Knittel B. Positron emission tomography and the blood brain barrier in Alzheimer's disease. In: New Brain Imaging in Cerebrovascular Diseases. Cahn J. Lassen NA (Eds.), John Libbey Eurotext, Montrouge, France, 1985, pp. 85-93.

8.      Friedland RP, Budinger TF, Jagust WF, Koss E, Derenzo S, Huesman RH, Yano Y. Positron tomography and the differential diagnosis and pathophysiology of Alzheimer's disease. In: Senile Dementia of the Alzheimer Type, Traber J, Gispen WH, (Eds.), Springer-Verlag Co., Heidelberg, 1985, pp. 124-133.

9.      Friedland RP. Neurological aspects and cognitive dysfunction imaging and dementia, and Neuroanatomy of dementia. World Health Organization International Workshop on Epidemiology of Mental and Neurological Disease of the Elderly. Published in Chinese by the Beijing Medical University, Institute of Mental Health, Peoples Republic of China, pp. 4.1-4,.8 and 6.1-6.6, 1987.

10.     Schapiro MB, Luxenberg JS, Kaye JA, Haxby JV, White B, Moore A, Friedland RP, Rapoport SI. Serial quantitative computed tomography (CT) analysis of brain morphometry in adult Down syndrome at different ages. In: New Trends in Aging Research, volume 15 Edited by G. Pepeu, B. Tomlinson, GM Wischik. pp. 141-152, 1988.

11.     Friedland RP, Luxenberg JS. Neuroimaging in dementia. In: Clinical Neuroimaging, Theodore W, (ed.), New York, Alan R. Liss, Inc., pp. 139-163, 1988.

12.     Friedland RP. Metabolic brain imaging techniques in dementia of the Alzheimer type. In: classification and diagnosis of Alzheimer's disease: An international perspective. World Health Organization, Geneva. Edited by Hovaguimian T, Henderson S, Khatchaturian Z, Orley J, Hogrefe and Huber Publishers, Geneva pp. 122-134, 1989.

13.     Friedland RP. Brain imaging and cerebral metabolism. In: Handbook of Neuropsychology Vol. 4. Eds. Boller F, Grafman J, Elsevier Science Publishers, pp. 195-209, 1990.

14.     Friedland RP, Jagust WJ. Positron and single photon emission tomography in the differential diagnosis of dementia. In: Dementia and Positron Emission Tomography. Edited by Duara R, New York, Wiley-Liss Publishers, pp. 161-177, 1990.

15.     Friedland RP. The cerebral circulation and the mechanisms of Alzheimer's disease: In: Aging of the brain: Cellular and molecular aspects of brain aging and Alzheimer's disease (Taniguchi Symposium on Brain Sciences, No. 13). Eds: Nagatsu T and Hayaishi O, Japan Scientific Societies Press, Tokyo and Karger, Basel, pp. 147-159, 1990.

16.     Friedland RP. Positron emission tomography in dementia. In: Psychogeriatrics: Biomedical and Social Advances. Eds. Hasegawa K, Homma A., Amsterdam, Excerpta Medica, pp. 157-160, 1990.

17.     Whitehouse PJ, Friedland RP, Strauss ME. Neuropsychiatric aspects of degenerative dementias associated with motor dysfunction. In: Textbook of Neuropsychiatry. Edited by S. Yudofsky, American Psychiatric Press, Washington, D.C., pp. 585-604, 1992.

18.     Friedland RP. Wilcock G.  Dementia. In: Oxford Textbook of Geriatric Medicine.  Edited by J.G. Evans and T.F. Williams, Oxford University Press, Oxford, pp. 483-489, 1993.

19.     Hedera P, Friedland RP. Normal pressure hydrocephalus. In: Neurobase, Ed, S. Gilman et al, Arbor Publishing Co. Rochester, NY (electronic publishing, 1995, updated in 2003).

20.     Friedland RP. Effects of aging and Alzheimer's disease on perception, attention and cognition: Relationships to driving performance In: Aging and Driving Ed.  By K. Johannson, and C. Lundberg, Karolinska Institutet, Stockholm, pp. 93-96, 1994.

21.     McRae A, Rodgers-Johnson P, Friedland RP (Editors). Neurodegenerative Disorders: Common molecular mechanisms, Molecular and Chemical Neuropathology 28;1-3:1-306,1996.

22.     Friedland RP, Smyth K, Esteban-Santillan C, Koss E, Cole R, Lerner AJ, Strauss M, Whitehouse PJ, Petot G, Rowland DY, Debanne S.  Premorbid environmental complexity is reduced in patients with Alzheimer’s disease (AD) as compared to age and sex matched controls: Results of a Case-Control Study.  Proceedings of the Fifth International Conference on Alzheimer’s Disease and Related Disease, K. Iqbal, B. Winblad, H. Wisniewsk,i Eds. Neurobiology of Aging, John Wiley and Sons, New York, pp. 33-37, 1997.

23.     Friedland RP, Kalaria R, Berridge M, Miraldi F, Hedera P, Reno J, Lyle L, Marotta CA. Neuroimaging of vessel amyloid in Alzheimer’s disease.  In: Cerebrovascular Pathology in Alzheimer’s Disease J. De la Torre, V. Hachinski, Eds. Annals of the New York Academy of Sciences, Vol. 826:242-247,1997.

24.     Friedland RP. Wilcock G.  Dementia. In: Oxford Textbook of Geriatric Medicine.  (2nd edition) Edited by J.G. Evans and T.F. Williams, Oxford University Press, Oxford, pp. 922-932, 2000.

25.     Cohen DL, Hedera P, Premkumar DRD, Friedland RP, Kalaria RN. Amyloid-ß protein angiopathies masquerading as Alzheimer’s Disease? Cerebrovascular Pathology in Alzheimer’s Disease. J. De la Torre, V. Hachinski, Eds. Annals of the New York Academy of Sciences, Vol. 826:390-395, 1997.

26.     Korczyn AD, Kahana E, Friedland RP.  Education and dementia. In: Handbook of Aging and Mental Health Ed. by J. Lomranz, Plenum Press, New York, pp. 449-458, 1998.

27.     Friedland RP. Prospects for noninvasive imaging of brain amyloid ß in Alzheimer’s disease. Annals of the New York Academy of Sciences 903:123-128, 2000.

28.     Perry G, Nunomura A, Friedlich A, Boswell M, Brazdil L, Jones P, Rottkamp C, Zhu X, Raina A, Hirai K, Friedland RP, Shi J, Aliev G, Cash A, Russell R, Wataya T, Shimohama S, Atwood C, Smith MA. Factors controlling oxidative damage in Alzheimer disease: Metals and mitochondria. In: Free Radicals in Chemistry, Biology and Medicine, T. Yoshikawa, S. Et al, Eds., pp. 417-423, 2000.

29.     Small GW, DeLeon MJ, Foster NL, Friedland RP, O’Brein JT. Clinical and post-mortem validation studies. IN: Neuroimaging Research in Alzheimer’s Disease: Observations and Issues. Neurobiology of Aging (in press).

30.     Friedland RP, Anosognosia, Encyclopedia of the Neurological Sciences, Harcourt Press, (in press).

31.     Friedland RP, Korczyn AD, Farrer L.  Position Paper: Genetic and Environmental risk factors for Alzheimer’s disease in Arabs residing in Israel. In: Drug Discovery and Development for Alzheimer’s Disease: 2000, Springer Pub. Co., H. M. Fillit, A.W. O’Connel, Eds., pp. 13-16. 2002.

32. Friedland RP. Should dietary modifications be recommended to lower the risk of Alzheimer’s Disease. In: The Diversity of Alzheimer's Disease - Different Approaches and Contexts Ed. By A. Leibing and L. Sheinkman, Rio de Janeiro: ColecoesIPUB, pp. 25-36, 2002

33. Bowirrat A, Friedland, RP, Korczyn AD. Epidemiology of Alzheimer’s disease. In: Brain Disease: Theraputic Stategies and Repair. O. Abramsky, et al, Eds., Martin Dunitz Ltd, Pub. London, 299-312, 2002.

 

top

 

LETTERS and BOOK REVIEWS

 

1.      Friedland RP, Bodis-Wollner I. Letter to the Editor: Absence of somatosensory evoked potentials in patients with anosognosia. Neurology 27:695-697, 1977.

2.      Yahr MD, Friedland RP. Letter to the Editor: Acute neurological forms for infectious mononucleosis, Reply. Archives of Neurology 34:651, 1977.

3.      Friedland RP. Letter to the Editor: Communicating hydrocephalus. Lancet ii:1188, 1977.

4.      Friedland RP. Letter to the Editor: Hematocrit and cerebral blood flow. Lancet 1:41, 1978.

5.      Friedland RP. Book Review: Essays on Kuru, Edited by Hornabrook RW. Archives of Neurology 36:183, 1979.

6.      Friedland RP. Letter to the Editor: Transmission of Creutzfeldt-Jakob disease. Lancet 11:1198, 1979.

7.      Friedland RP, Koss B. Letter to the editor: Endocrine effects: laterality of lesions. Stroke 12:888, 1981.

8.      Friedland RP, Morris B. Bender: In Memorial. International Journal of Neurosciences 21:151, 1983.

9.      Friedland RP, Budinger TF. Positron emission tomography in Alzheimer's disease. IEEE Spectrum 21:103, 1984.

10.     Friedland RP, St. John JN. Video game palsy: distal ulnar neuropathy in a video game enthusiast. New England Journal of Medicine 311:58-59, 1984.

11.     Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet i:228, 1985.

12.     Koss E, Friedland RP, Jagust WJ. Letter to the editor, reply: Early and late onset of Alzheimer-type dementia. American Journal of Psychiatry 143:272, 1986.

13.     Koss E, Friedland RP. Letter to the Editor (Reply): Differences between early and late onset Alzheimer-type dementia. Archives of Neurology 44:797-798, 1987.

14.     Koss E, Weiffenbach JM, Haxby JV, Friedland RP. Olfactory detection and recognition in Alzheimer's disease. Lancet 1:622, 1987.

15.     Friedland RP. Commentary on the NIH Consensus Conference on the Differential Diagnosis of Dementing Diseases. Alzheimer's Disease and Associated Disorders: An International Journal 2:17, 1988.

16.     Friedland RP, Koss E, Kumar A, Haxby JV. Letter to the Editor: Occurrence of motor vehicle crashes among patients with Alzheimer's disease: Reply. Annals of Neurology 24:782-786, 1988.

17.     Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober BA. Letter to the Editor: Cerebral metabolism in Alzheimer's disease, reply. Neurology 39:309-310, 1989.

18.     Friedland RP. Letter to the Editor: Normal Pressure Hydrocephalus, reply. Journal of the American Medical Association 264:336, 1990.

19.     Friedland RP. Book Review: Eponymists in Medicine: Alzheimer and the Dementias. Eds G.E. Berrios and H.L. Freeman. Neurology 42:1258, 1992.

20.     Friedland RP. Book Review: Dementia, A Clinical Approach. JL Cummings and DF Benson, Neurology 42:1648, 1992.

21.     Friedland RP. Book Review. Neurodevelopment, Aging and Cognition. Kostovic I, Snezevic S, Wisniewski HMI, Spilich GJ, Neurology (in press).

22.     Friedland RP. Letter to the Editor: Julius Hallervorden. Neurology 43: 1453, 1993.

23.     Friedland RP. Book Review: Hannah's Heirs: The Quest for the Genetic Origins of Alzheimer's Disease. Neurology 44:590, 1994.

24.     Friedland RP. Book Review: Alzheimer's Disease: Advances in Clinical and Basic Research, B. Corain et al, Eds., Neurology 44:1989, 1994.

25.     Friedland RP, Hedera P. Letter to the Editor, Reply: The prevalence of treatable dementia. Neurology 45:601, 1995.

26.     Friedland RP. Book Review: Alzheimer's disease. RD Terry et al, Eds.. Dementia. A. Burns, R. Levy (editors) Neurology 45:209-210, 1995.

27.     Friedland RP. Letter to the Editor: Fluorine-18. Trends in Biochemical Sciences, 20:17, 1995.

28.     Friedland RP, McMonagle JJ. Crisis of competence: Capacity to execute wills is tenuous for victims of Alzheimer’s disease. American Bar Association Journal, 82:80, 1996.

29.     Friedland RP, Gilman S, Morris JC. Dementia in the elderly: is it Alzheimer’s? Patient Care 30,18-40, 1996.

30.     Ford A, Mefrouche Z, Friedland RP, Debanne SM. Smoking and cognitive impairment.  Letter (Reply) Journal of the American Geriatrics Society 44(8):905-9, 1996.

31.     Friedland RP. Molecular Mechanisms of Dementia, W. Wasco, RE Tanzi, Humana Press, 1977, Neurology 49:1192, 1997.

32.     Lerner A V, Friedland RP, The Evolution of Alzheimer’s disease (Book Review) The Gerontologist, 36:713-714, 1997.

33.     Debanne SM, Rowland DY, Friedland RP, Lerner A.  Smoking and Alzheimer’s disease: Reply The Lancet, 295, 1997.

34.     Friedland RP.  Neuroimaging in dementia.  Mediguide for Clinical Neurology, V1(4)1-8, 1997.  L. Delacorte Publishers, 1997. 

35.     Friedland RP and Krasner B. Managing Alzheimer’s patients, Letter to the Editor. Science 282:2194-2195, 1998.

36.     Friedland RP, Book Review: Alzheimer’s Disease: First Steps in Caring and Treatment, D. Kuhn, Hunter House Publishers, Journal of Alzheimer’s Disease 1:425.

38. Friedland RP, Kishikawa Y, Vega V. Suicide and Alzheimer’s disease. Journal of Geriatric Psychiatry 10:484-485, 2002.

39. Friedland RP, Etribi A, Korczyn AD, Fillit H. The First International Symposium on Alzheimer’s disease in the Middle East. World Neurology 16:10, 2001.

 

 

top

 

INVITED PRESENTATIONS

 

1.      Weinstein EA, Friedland RP. Behavioral disorders associated with hemi-inattention. Hemi-inattention and Hemisphere Specialization Symposium, Mount Sinai School of Medicine, New York, February 1976.

2.      Friedland RP. Cerebral blood flow in aging and dementia: A review. Workshop on non-invasive xenon cerebral blood flow applications, Cerebrovascular Clinical Research Center Workshop, Phoenix, February, 1979.

3.      Friedland RP, Budinger TF. Positron tomography and the diagnosis of Alzheimer's disease. AARP-NIA Conference on the Diagnosis of Alzheimer's Disease, Bethesda, Maryland, December, 1983.

4.      Budinger TF, Huesman RH, Knittel BC, Friedland RP, Ganz E, Derenzo SE. Modeling dynamic processes of metabolism, permeability and flow in the brain. Nobel Conference VII on the Metabolism of the Human Brain Studied with Positron Emission Tomography, Stockholm, May, 1983.

5.      Friedland RP. Eye movement abnormalities in Alzheimer's disease. Oculomotor System Society, Berkeley, California, February, 1984.

6.      Friedland RP. Positron imaging in dementia: implications for diagnosis and pathophysiology. Alzheimer's Disease: A Conference on Assessment and Treatment of Patients and Caregivers, Office of Geriatrics and Extended Care, VA Central Office, Palo Alto, June, 1984.

7.      Friedland RP. The etiology of Alzheimer's disease; recent developments. San Francisco Neurological Society, Pebble Beach, California, March, 1984.

8.      Friedland RP. Positron emission tomography and the blood brain barrier in Alzheimer's disease. Beaune Conference on Acute Cerebrovascular Diseases Pharmacology, Beaune, France, October, 1984.

9.      Friedland RP. PET in the early diagnosis of Alzheimer's disease. International Tropan-Bayer Symposium on Brain Aging, Cologne, November, 1984.

10.     Friedland RP. Regional alterations of glucose use in Alzheimer's disease.  Symposium on Biological Correlates of Cognitive Impairment in Alzheimer's Disease, European International Neuropsychological Society, Copenhagen, June 19985, Journal of Clinical and Experimental Neuropsychology 7:168, 1985 (Abstract).

11.     Friedland RP. Applications of PET to neuropsychology. Symposium on Diagnostic Imaging of the Brain, European International Neuropsychological Society, Copenhagen, June, 1985.

12.     Friedland RP. PET scanning and dementia. American Society of Neuroimaging, Tampa, Florida, February, 1985.

13.     Friedland RP, Jagust W. Alzheimer's disease and the blood-brain barrier. San Francisco Neurological Society, Reno, March, 1985.

14.     Friedland RP. Positron imaging in dementia: diagnostic and physiologic implications, Symposium on State of the Art Research on Alzheimer's Disease, American Psychological Association, Los Angeles, August, 1985.

15.     Budinger TF, Friedland RP. Brain imaging on dementia. Brooklodge Symposium, Cognitive dysfunctions: Therapeutic approaches. Upjohn Company, Kalamazoo, MI, June 6, 1985.

16.     Friedland RP. Positron tomography and physiologic imaging: Contrast to MRI. Neuroimaging Course, American Academy of Neurology, New Orleans, April, 1986.

17.     Friedland RP. Cerebral metabolism and blood flow in Alzheimer's disease and related disorders. Symposium on Consensus Development in the Diagnosis of Alzheimer's Disease. World Health Organization, Geneva, Switzerland, March, 1987.

18.     Friedland RP, Haxby J, Grady C, Koss E, Horwitz B, Schapiro MB, Kumar A, Rapoport SI. Longitudinal studies of neocortical metabolic alterations in dementia of the Alzheimer type. World Congress of Neurosciences, Budapest, August, 1987. Neuroscience 22(Suppl):S2, 1987.

19.     Friedland RP. The 2-deoxy-D-glucose method and PET methodology. World Congress of Neurosciences, Budapest, August, 1987. Neuroscience 22(Suppl):S107, 1987.

20.     Friedland RP. The diagnosis of dementia. Italian-USA Conference on Epidemiological Studies on Aging. Taormina, Sicily, November, 1987.

21.     Friedland RP. Neurological aspects and cognitive dysfunction in aging and dementia, and Neuroanatomy of dementia. World Health Organization International Workshop on Epidemiology of Mental and Neurological disorders in the Elderly, Beijing, November, 1987.

22.     Friedland RP. Imaging molecular pathology: Studies in dementing illness. Imaging brain chemistry: Principles and practice, Johns Hopkins Medical Institutions, March, 1988.

23.     Friedland RP. Brain imaging in Alzheimer's disease. The Fourth Congress of the International Psychogeriatric Association, Tokyo, September, 1989.

24.     Friedland RP. Chairperson and speaker, Symposium on Recent Advances in Neuroimaging Investigations of Dementing Illnesses. American Geriatrics Society and American Federation for Aging Research, Boston, May, 1989.

25.     Friedland RP. Chairperson and speaker, Intensive: Managing the Social Burden of Alzheimer's Disease. American Society on Aging, Washington, D.C., March, 1989.

26.     Friedland RP. The brain in Alzheimer's disease. Symposium: Breakthroughs in Gerontological Research. American Society on Aging, Washington, D.C., March, 1989.

27.     Friedland RP. The neuroanatomy of dementia. Symposium on Alzheimer's Disease Research in Japan, National Institute of Neuroscience, Tokyo, March, 1989.

28.     Friedland RP. The Aging Brain. American Society of Neuroradiology Course on Basic Sciences, Chicago, August, 1989.

29.     Friedland RP. The diagnosis and management of dementia. Summer Institute in Research on Aging, National Institute on Aging, Airlie, Virginia, July, 1989.

30.     Friedland RP. Brain metabolism in the neuro-degenerative disorders. The Role of Environmental Agents in Neurotoxicity. Environmental Health Institute Workshop, Stockbridge, May, 1990.

31.     Friedland RP. The cerebral circulation and the mechanisms Alzheimer's disease. The 13th Taniguchi International Symposium on Brain Sciences, La Jolla, CA, January, 1990.

32.     Friedland RP. Positron emission tomography and imaging in Alzheimer's disease. Symposium: Recent advances in the understanding of Alzheimer's disease. Foundation of American Societies for Experimental Biology,  Washington, DC, April, 1990.

33.     Friedland RP. Comparative drug development and therapy for Alzheimer and multi-infarct dementia: An American perspective. Japan Neuroscience Advisory Committee, Bristol-Myers Research Institute, Ltd., Tokyo, November, 1990.

34.     Friedland RP (Chairman). Symposium on Physiological Imaging Studies of Age Related Brain Disorders. International Psychogeriatric Association, Jerusalem, August 1991.

35.     Friedland RP. What is new in understanding, assessing, and treating Alzheimer's disease. Scientific Conference of the Ohio Network of Educational Consultants in the Field of Aging, Cleveland State University, April 19, 1991.

36.     Friedland RP. The Alzheimer patient: clinical picture and differential diagnosis. American Academy of Neurology Satellite Symposium: Neuroscience and the Socioeconomic Challenge of Alzheimer's disease (Chairman and Speaker) San Diego, May 1992.

37.     Friedland RP. Epidemiology and neurobiology of the multiple determinants of Alzheimer's disease. First Berkshire Neuroscience Symposium, Hancock, MA , July 1992.

38.     Friedland RP. Brain imaging in frontal lobe dementia, Second International Conference on Frontal Lobe Degeneration of Non Alzheimer Type. Lund, Sweden, September 1992.

39.     Friedland RP. Development of a monoclonal antibody for imaging ß amyloid in vivo. Progress in the diagnosis of Alzheimer's disease. National Caregiving Foundation, Rancho Mirage, CA, November 1993.

top

40.     Friedland RP, Co-Chairperson. Alzheimer's disease special interest social. Society for Neuroscience, Washington DC, November 1993.

41.     Friedland RP. Driving and behavior in Alzheimer's disease. Dementia and Driving Consensus Meeting, Swedish National Road Administration, Borlange, Sweden, September 1994.

42.     Friedland RP. Perceptual mechanisms and motor vehicle crashes in Alzheimer's Disease. Aging and Driving Symposium. Swedish Medical Society, Karolinska Institutet, Stockholm, September 1994.

43.     Friedland RP. Major nonpharmacological management issues in Alzheimer's disease. Dementia Update, American Academy of Neurology Annual Meeting , Post-graduate course, San Francisco, March, 1996.

44.     Friedland RP. Interventions to prevent driving. Driving and Dementia: Research, Practice and Policy. Washington University, St. Louis, May 1996.

45.     Friedland RP.  Driving behavior in Alzheimer’s disease.  National Criteria for Medical Evaluation for Driver Licensure Working Group, Association for the Advancement of Automotive Medicine, Washington University, St. Louis, May 1996.

46.     Friedland RP.  Diagnosis and neuroimaging of Alzheimer’s disease: Disciplinary and diagnostic issues in dementia.  12th Annual Alzheimer’s Disease Symposium, University of Tennessee Medical Center at Knoxville, May 1996.

47.     Friedland RP.  The placebo effect and Alzheimer’s disease drug studies. The Third Tel Aviv University Alzheimer’s Disease Conference, Tel Aviv, May 1996.

48.     Friedland RP.  (Plenary speaker) Denial and dementia..  Alzheimer’s Disease International, Twelfth International Conference, Jerusalem, October 1996.

49.     Friedland RP. Antibody imaging  in neurodegeneration. Cerebrovascular pathology in Alzheimer’s disease. New York Academy of Sciences, November 1996.

50.     Friedland RP. Major nonpharmacological management issues in Alzheimer's disease. Dementia Update, American Academy of Neurology Annual Meeting , Post-graduate course, San Francisco, April 1997.

51.     Friedland RP.  Neuroimaging of vessel amyloid in Alzheimer’s disease, OHOLO 41st Conference on Progress in Alzheimer’s and Parkinson’s Disease.  Eilat, Israel, May 1997.

52.     Friedland RP.  Amyloid imaging in Alzheimer’s disease, Fourth Tel Aviv University Alzheimer’s disease conference, May 1997.

53.     Friedland RP.  Cross-cultural epidemiology of dementia. International Psychogeritaric Association, Jerusalem, August 1997.

54.     Friedland RP. International issues in the epidemiology of dementia: Considerations from the perspective of natural selection. American Public Health Association. Indianapolis, November 1997.

55.     Friedland RP.  Management and Treatment of Alzheimer’s Disease(s). Thirteenth Annual Alzheimer’s Disease Symposium, University of Tennessee, Knoxville, May 1997.

56.     Friedland RP.  Evaluation of the presence of latent cytomegalovirus infection in cerebral arteries in Alzheimer’s disease. 4th Congress of the European Society for Clinical Neuropharmacology, Eilat, Israel, December 1997.

57.     Friedland RP.  Prospects for neuroimaging in early diagnosis and monitoring of therapy of Alzheimer’s disease.  Neuroimaging Workshop International Conference on Alzheimer’s Disease and Associated Disorders, Amsterdam, July 1998.

58.     Whitehouse PJ, Friedland RP.  Activities, appreciation and aging: Lesson for behavioral management.  Workshop "Aging 2000” Symposium: Behavioral approaches to the treatment of Alzheimer’s disease.  International Psychogeriatric Association, Munich, September 1998.

59.     Friedland RP. Laterality of frontotemporal lesions and behavior.  Third International Conference on Frontal Dementias, University of Lund, Sweden August 1998.

60.     Friedland RP.  Alzheimer’s disease and the 21st Century, Japan Well Aging Society, Annual meeting, Tokyo, November 1998.

61.     Friedland RP. Imaging amyloid in Alzheimer brain.  Vascular factors in Alzheimer’s Disease International Meeting, Northumberland, UK, May 1999.

62.     Friedland RP. Genetic and environmental risk factors for Alzheimer’s disease in Kenya and Israel.  Neuroscience in Developing Countries: Getting Around the Problems. Society for Neuroscience Workshop, November 1998, Los Angeles.

63.     Ogunniyi S, Friedland RP.  Epidemiology of dementia in Africa: The Nigerian experience.  World Federation of Neurology Research Group on Dementia, Johannesberg, September 1999.

64.     Friedland RP.  The very high prevalence of Alzheimer’s disease in an Arab population is not explained by apolipoprotein E 4 allele frequency. World Federation of Neurology Research Group on Dementia, Johannesberg, September 1999.

65.     Friedland RP. Biological markers for Alzheimer’ s disease. Seventh Tel Aviv University Alzheimer’s Disease Conference, Tel Aviv, June 1999.

66.     Friedland RP. Keynote speaker: Implications of evolutionary biology for our understanding of neurodegenerative disease. World Federation of Neurology Research Group on Neuroepidemiology, San Diego, May 2000.

67.     Friedland RP.  Apolipoprotein E genotype and dietary lipid interactions as Alzheimer’s disease risk factors. Eighth Tel Aviv University Alzheimer’s Disease Conference, Tel Aviv, June 2000.

68.     Friedland RP. Gene-environment interactions and the causal web of Alzheimer’s disease:Implications fordrug studies. Fifth International Conference on the Progress in Alzheimer’s Disease and Parkinson’s Disease. Kyoto, April 2001.

69.     Friedland RP. Alzheimer’s disease and diet. American Academy of Neurology,  Kickoff Presentations, Philadelphia, May 2001

70.     Friedland, RP. Genetic and environmental risk factors for Alzheimer’s disease in Arabs residing in Israel. Institute for the Study of Aging, First Annual Investigators Meeting, Tarrytown, NY, November 2000.

71.     Friedland RP, Lipid metabolism, statins and Alzheimer’ s disease (Discussant). National Lipid Education Council, Tucson, AZ, January, 2001.

72.     Friedland RP, Alzheimer’ s disease and evolution: Lessons from the old world. Thirteenth Annual Alzheimer’ s Disease Symposium, University of Tennessee, Knoxville, Gatlinburg, TN, June 2001.

73.     Friedland RP, Farrer LA, Bowirrat A, Launer LJ, Jacobsen DW, Mizrahi E, Baldwin C, Korczyn A.  High Alzheimer’s disease prevalence and low apolipoprotein E e4 allele frequency in Arabs residing in Israel.  Society of Neuroscientists of Africa, Nairobi, May 2001.

74. Friedland RP. Mental activity in midlife as a protective factor for Alzheimer’s disease, Eighth Tel Aviv University Alzheimer’s Disease Conference, Tel Aviv, June 2001.

top

75. Friedland RP. Genetic risk factors for Alzheimer’s disease in Arabs residing in Israel. Institute for the Study of Aging, Second Annual Investigators Meeting, Purchase, NY, November 2001.

76. Friedland RP. Diet and Alzheimer’s disease. Eight International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, July 2002.

77. Friedland RP, Clinical factors of Alzheimer’s disease and vascular dementia. Third World Congress on Vascular factors in Alzheimer’s Disease, Kyoto, April 2002.

78. Friedland RP, Approaches for the development of early diagnosis of Alzheimer’s disease.  Third Annual Aluminum and Health Forum, Council on Aluminum and Health, Tokyo, April, 2002.

79. Friedland RP, Mental and physical activity and Alzheimer’s risk. 2002 Annual University  of California, Irvine, Research Conference, May 2002.

80. Friedland, RP, Farrer L. Genetic risk factors for Alzheimer’s disease in Arabs. Institute for the Study of Aging, Third Annual Investigators Meeting, Purchase, NY, October 2002.

81. Friedland RP. Evolutionary perspectives on diet and brain aging. Nutrition and Aging XVII: Nutritional Challenges in the Elderly, Little Rock, Arkansas, September 2002.

82. Friedland RP. Dietary and genetic interactions in Alzheimer’s disease. Nutritional Modulation of Aging and Age –Related Diseases, American Aging Association Annual Conference, Boston, June, 2003.

83. Friedland RP, Lipids Diet and Alzheimer’s disease. International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG), Goteborg, August, 2003

84. Friedland RP, Update on early diagnosis of vascular dementia and progress in amyloid Beta protein imaging. International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG), Goteborg, August, 2003

85. Friedland, RP, Cerebral amyloid angiopathy is not directly linked to the pathogenesis of Alzheimer’s disease. Challenging Views of Alzheimer’s Disease Round 2, Cincinnati, July 2003.

86. Friedland RP, Genetic and environmental risk factors for Alzheimer’s disease in Arabs residing in Israel. Institute for the Study of Aging, Fourth Annual Investigators Meeting, Teaneck, NJ, Sept. 2003.

87. Friedland, RP. Lipid metabolism, diet and Alzheimer’s disease. Research Institute For Brain and Blood Vessels, Akita, Japan, January, 2004.

 

top

 

ABSTRACTS AND PRESENTATIONS

 

1.      Abeliuk ON, Friedland RP, Nakada T, Remler MP. Multifocal glioblastoma involving both hemispheres, brainstem and cerebellum with familial tendency. Federation of Western Societies of Neurological Science, 1981.

2.      Budinger TF, Yen CK, Yano Y, Friedland RP, O'Brien HA: Blood brain barrier permeability and intravascular flow volume measurements using rubidium-82 and dynamic positron emission tomography. Society of Nuclear Medicine, St. Louis, June 1981. Journal of Nuclear Medicine 22:15, 1981.

3.      Budinger TF, Yen CK, Friedland RP. Blood brain barrier permeability and intravascular flow volume measurements using rubidium-82 and dynamic positron emission tomography. International Symposium on Cerebral Blood Flow and Metabolism, St. Louis, Missouri, June 19-24, 1981. Journal of Cerebral Blood Flow and Metabolism I (Supp.1):S47, 1981.

4.      Friedland RP, Budinger TF, Yen CK, Sargent T, Mathis C, Yano Y. Positron emission tomographic approaches to the study of dementia pathophysiology. International Study Group on the Pharmacology of Memory Disorders Associated with Aging, Zurich, Switzerland,  April 3-5, 1981.

5.      Friedland RP, Meibach RC. Effects of acetylcholinesterase inhibitors on 2-deoxy-D-glucose uptake in the rat brain. Society for Neuroscience, October, 1981, Los Angeles, California. Society for Neuroscience Abstracts 7:494, 1981.

6.      Friedland RP, budinger TF, Ganz E, Yano T, Mathis C, Huesman R, Knittel B, Ober BA, Koss B. Dementia pathophysiology: X-ray computed tomography and dynamic emission tomographic studies with 18-fluorodexoyglucose and rubidium-82. Society for Neuroscience, Minneapolis, Minnesota, November 1, 1982. Society for Neuroscience Abstracts 8(1):30, 1982.

7.      Friedland RP, Ganz E, Yano Y, Budinger T, Koss B, Ober BA. Positron emission tomography: A new approach to the dementias. San Francisco Neurological Society, Yosemite National Park, California, March 1982.

8.      Friedland RP, Koss B, Ober BA, Budinger TF, Ganz E, Yano Y. Neuropsychological correlates of regional cerebral metabolic alterations in Alzheimer-type dementia. International Neuropsychological Society, International Neuropsychological Society Bulletin, p. 22, September 1982.

9.      Koss B, Ober BA, Friedland RP, Budinger TF, Ganz E, Yano Y, Delis DC. Stroop interference effect in Alzheimer-type dementia: Relationships to severity of cognitive impairment and regional alterations in cerebral glucose metabolism: International Neuropsychological Society, Mexico City, February 1, 1983. International Neuropsychological Society Bulletin, p. 25, September 1982.

10.     Tompkins-Ober BA, Koss B, Friedland RP, Budinger TF, Ganz E, Delis DC. Verbal learning and memory functions in Alzheimer-type dementia. Society for Neuroscience, Minneapolis, Minnesota, November 1982. Society for Neuroscience Abstracts 8(II):629, 1982.

11.     Tompkins-Ober BA, Koss B, Friedland RP, Budinger TF, Ganz E, Yano Y, Delis DC. Verbal learning and visual recognition memory functions in Alzheimer-type dementia: Relationships to alternations in regional cerebral metabolic rates. International Neuropsychological Society, Mexico City, February 1983. International Neuropsychological Bulletin, p. 35, September 1982.

12.     Koss B, Friedland RP, Ober BA. Lateral asymmetry in cerebral metabolism: a prominent feature of Alzheimer-type dementia. International Neuropsychological Society, Houston, February 1984. International Neuropsychological Society Bulletin, p. 24, October 1983.

13.     Koss B, Jones A. Friedland RP, Ober B. Saccadic intrusions in Alzheimer-type dementia. American Psychological Association, Anaheim, August 1983.

14.     Friedland RP. The use of positron imaging in the differential diagnosis of dementia. San Francisco Neurological Society, Konocti Harbor, March 1983.

15.     Friedland RP, Budinger TF, Yano Y, Huesman R, Knittel B, Derenzo S, Koss B, Ober BA. Regional cerebral metabolic alterations in Alzheimer-type dementia: Studies with 18-Fluorodeoxyglucose. International Symposium on Cerebral Blood Flow and Metabolism, Paris, June 1983.

16.     Friedland RP, Yano Y, Budinger TF, Ganz E, Huesman RH, Derenzo SE, Knittel B. Quantitative evaluation of blood brain barrier integrity in Alzheimer-type dementia: Positron emission tomographic studies with rubidium-82. Satellite Symposium on Effects on Aging on Regulation of Cerebral Blood Flow and Metabolism, San Remo, June 1983.

17.     Ober BA, Dronkers NF, Koss B, Friedland RP, Delis DC. Retrieval from semantic memory in Alzheimer-type dementia. International Neuropsychological Society, Houston, February 1984. International Neuropsychological Society Bulletin, p. 26, October 1983.

18.     Koss E, Ober BA, Friedland RP, Jagust WJ. Cognitive deterioration in Alzheimer-type dementia is related to age and cerebral metabolic asymmetries. International Neuropsychological Society, San Diego, February 1985, International Neuropsychological Society Bulletin, p. 20, November 1984.

19.     Lakshiminarayanan V, Friedland RP, Muller E, Koss E, Stark L. Integrity of the vestibular-ocular reflex in Alzheimer's Disease. Society for Neuroscience, Los Angeles, October 1984. Society for Neuroscience Abstracts 10 (Part 2):775, 1984.

20.     Friedland RP, Prusiner SB, Jagust W, Koss E, Budinger TF. Regionally diminished glucose utilization in Creutzfeldt-Jakob Disease is similar so that in Alzheimer's disease. American Academy of Neurology, Boston, April 1984. Neurology (Supp. 1) 34:122, 1984.

21.     Dronkers NF, Ober BA, Simpson GV, Friedland RP. Neuropsychological and physioanatomical features of suspected Pick's disease. International Neuropsychological Society, San Diego, February 1985, International Neuropsychological Society Bulletin, p. 13, November 1984.

22.     Friedland RP, Budinger TF, Jagust WJ, Yano Y, Huesman RH, Knittel B, Koss E, Ober BA. Anterior-posterior and lateral hemispheric alterations in cortical glucose utilization in Alzheimer's Disease. Society of Nuclear Medicine, Los Angeles, CA, June 1984. Journal of Nuclear Medicine 25:57, 1984.

23.     Friedland RP, Budinger TF, Prusiner SB, Jagust WF. Bitemporal hypometabolism in Creutzfeldt-Jakob disease measured by PET with (F-18) 2-fluorodeoxyglucose. Society of Nuclear Medicine, Los Angeles, June 1984. Journal of Nuclear Medicine 25:109, 1984.

24.     Jagust W, Friedland RP, Budinger TF. Differentiation of normal pressure hydrocephalus from Alzheimer's disease by 18-F-fluorodeoxyglucose positron emission tomography. Federation of Western Societies of Neurological Science, Napa, California, February 1984.

25.     Jagust WJ, Friedland RP, Budinger TF. Cerebellar hypermetabolism in neurodegenerative disease. American Academy of Neurology, Dallas, Texas, April/May 1985. Neurology (Suppl 1) 35:1385.

26.     Jagust WJ, Friedland RP, Budinger TF, Huesman RH, Knittel B. Methodological factors affecting PET measurements of glucose metabolism. American Academy of Neurology, Dallas, April/May 1985. Neurology (Suppl 1) 35:138, 1985.

27.     Friedland RP, Jagust WJ, Budinger TF, Huesman RH, Knittel B. Blood-brain barrier permeability studies in Alzheimer's disease. American Academy of Neurology, Dallas, Texas, April/May 1985. Neurology (Suppl 1) 35:177, 1985.

28.     Friedland RP, Jagust WJ, Budinger TF, Huesman RH, Knittel B. Methodological factors affecting the accuracy of metabolic measurements in PET studies with (18F)-2-fluoro-2-deoxy-D-glucose (FDG). International Symposium on Cerebral Blood Flow and Metabolism, Lund, June 16-20, 1985.

29.     Friedland RP, Jagust WJ, Budinger TF, Yano Y, Huesman RH, Knittel B. Dynamic PET studies of blood-brain permeability in Alzheimer's disease. Society of Nuclear Medicine Houston, June 1985. Journal of Nuclear Medicine 26:103, 1985.

top

30.     Friedland RP, Koss E, Jagust WJ. Lateral hemispheric asymmetries of glucose use in Alzheimer's disease: relationships to behavior, age of onset and prognosis. International Symposium on Cerebral Blood Flow and Metabolism, Lund, Sweden, June 1985.

31.     Dronkers NF, Koss E, Friedland RP, Wertz RT. "Differential" language impairment and language mixing in a polyglot with probable Alzheimer's disease. International Neuropsychological Society. June 1986, Journal of Clinical and Experimental Neuropsychology 8, 1986.

32.     Friedland RP, Jagust WJ, Ober BA, Dronkers NF, Koss E, Simpson GV, Ellis WG, Budinger TF. The pathophysiology of Pick's disease: a comprehensive case study.  American Academy of Neurology, New Orleans, May 1985. Neurology 36 (Suppl 1):268, 1986.

33.     Friedland R, Koss E, Jagust WJ, Borcich J. Familial subcortical arteriosclerotic encephalopathy (SAE) in two families: studies with X-ray CT, NMR, and PET. American Academy of Neurology, New Orleans, May 1986. Neurology 36 (Suppl 1):102, 1986.

34.     Friedland RP, Smith C, Jagust WJ, Sokoloff L, Budinger TF. Diminished rates of cortical glucose utilization in Alzheimer's disease are not related to plasma beta-hydroxybutyrate concentrations. Society for Neuroscience, November 1986, Abstracts. Society for Neuroscience 12(Part 2):945, 1986.

35.     Jagust WJ, Friedland RP, Budinger TF, Huesman RH, Mazoyer BM, Brennan KM, KNittel FL, Yano Y, Mathis CA. Kinetics of regional cerebral glucose transport and phosphorylation in Alzheimer's disease. American Academy of Neurology, New Orleans, May 1986. Neurology 35(Suppl 1):264, 1986.

36.     Jagust WJ, Friedland RP, Budinger TF, Huesman R, Mazoyer BM, Brennen KM, Knittel BL, Yano Y, Mathis CA. Cerebral glucose transport and phosphorylation in Alzheimer's disease. Society of Nuclear Medicine, Washington DC, June 1986. Journal of Nuclear Medicine 27:955, 1986.

37.     Koss E, Weiffenbach JM, May C, Haxby JV, Friedland RP. Variability of olfactory dysfunction in Alzheimer's disease. Society for Neuroscience, November 1986. Abstracts, Society for Neurosciences 12(part 2):945, 1986.

38.     Schapiro MB, Luxenberg JS, Kaye JA, Haxby JV, White B, Friedland RP, Rapoport SI. Serial quantitative computed tomography (CT) analysis of brain morphometry in adult Down's syndrome at different ages. International Symposium on Aging Research, Florence, 1987.

39.     Friedland RP, Jagust WJ, Budinger TF, Koss E, Ober BA. Consistency of temporal-parietal cortex hypometabolism in probable Alzheimer's disease (AD) - relationships to cognitive decline. American Academy of Neurology, New York, April 1987. Neurology 37(Suppl 1):224, 1987.

40.     Friedland RP, Jagust WJ, Budinger TF, Koss E, Ober BA, Dronkers NF, Swain BE. Consistency of temporal-parietal cortex hypometabolism in probable Alzheimer's disease: Relationships to cognitive decline. International Symposium on Cerebral Blood Flow and Metabolism, Montreal, June 1987. Journal of Cerebral Blood Flow and Metabolism 7(Supp 1):5403, 1987.

41.     Haxby JV, Grady CL, Friedland RP, Rapoport SI. Neocortical metabolic abnormalities precede memory cognitive impairments in early dementia of the Alzheimer type: Longitudinal confirmation. International Symposium on the Pharmacology of Memory Disorders Associated with Aging. Zurich, Switzerland, January 1987.

42.     Haxby JV, Grady CL, Koss E, Friedland RP, Rapoport SI. Heterogeneous metabolic and neuropsychological patterns in dementia of the Alzheimer type: cross-sectional and longitudinal studies. American Academy of Neurology, New York, April 1987. Neurology 37(Suppl 1):159, 1987.

43.     Haxby JV, Grady CL, Koss E, Friedland RP, Rapoport SI. Longitudinal study of brain metabolism and neuropsychological heterogeneity in dementia of the Alzheimer type: Evidence for subtypes. International Symposium on Cerebral Blood Flow and Metabolism, Montreal, June 1987. Journal of Cerebral Blood Flow and Metabolism 7(Suppl 1):S377, 1987.

44.     Haxby JV, Luxenberg J, Grady CL, Koss E, Friedland RP, Rapoport SI. Lateral ventricular asymmetry correlates with neuropsychological and brain metabolic asymmetries in Alzheimer type dementia. International Neuropsychological Society, Washington, DC, Journal of Clinical and Experimental Neuropsychology 9:80, 1987.

45.     Jagust WJ, Friedland RP, Koss E, Ober BA, Mathis CA, Huesman RH, Budinger TF. Progression of regional cerebral glucose metabolic abnormalities in Alzheimer's Disease. American Academy of Neurology, New York, Neurology 37(Suppl 1): 156, April 1987.

46.     Jagust WJ, Friedland RP, Koss E, Ober BA, Mathis CA, Huesman RH, Budinger TF. Sequential studies of regional cerebral glucose metabolism in Alzheimer's disease. International Symposium on Cerebral Blood Flow Metabolism, Montreal, June 1987. Journal of Cerebral Blood Flow and Metabolism 7:(Suppl 1):S414, 1987.

47.     Kaye JA, Atack J, May D, Daly E, Kaufman S, Luxenberg J, Beal MF, Rapoport SI, Friedland RP, Milstein S. Extrapyramidal signs in dementia of the Alzheimer Type (DAT): Cerebrospinal fluid (CSF) acetylcholinesterase (AchE), somatostatin and neuropeptide Y. American Academy of Neurology, New York, Neurology 37(Suppl 1):155, April 1987.

48.     Kaye JA, Grady CL, Haxby JV, Moore A, Friedland RP, Rapoport SI. Reversibility of metabolic and cognitive deficits in normal pressure hydrocephalus (NPH) following shunt surgery. American Neurological Association, San Francisco, October 1987. Annals of Neurology 22:124, 1987.

49.     Kaye JA, Kay AP, May C, Atack J, Daly E, Kaufman S, Friedland RP, Sweeney DJ, Milstein S, Luxenberg J, Rapoport SI. Cerebrospinal fluid (CSF) monoamine markers are reduced in dementia of the Alzheimer type (DAT) with extrapyramidal features. American Academy of Neurology, April 1987. Neurology 376(Suppl 1):332, 1987.

50.     Kaye JA, Luxenberg JS, Rapoport SI, Friedland RP. Age-related acceleration of cerebral atrophy in healthy men and women measured by quantitative computed X-ray tomography, American Geriatrics Society, New Orleans, May 1987.

51.     Kaye JA, May C, Atack J, Daly E, Sweeney D, Beal MF, Kaufman S, Milstein S, Friedland RP, Rapoport SI. Cerebrospinal fluid (CSF) neurotransmitter markers in the myoclonic subtype of dementia of the Alzheimer type (DAT). American Neurological Association, San Francisco, October 1987. Annals of Neurology 22:121, 1987.

52.     Koss E, Friedland RP, Luxenberg JS, Moore A. Effects of occupational toxin exposure on regional cerebral glucose utilization and behavior in probable Alzheimer's disease (AD). International Symposium on Cerebral Blood Flow and Metabolism, Montreal, June 1987. Journal of Cerebral Blood Flow and Metabolism 7(Suppl 1):S402, 1987.

53.     Koss E, Haxby JV, Burg C, Rice M, Friedland RP, Rapoport SI. Optimally healthy individuals do not show decreases in verbal memory with aging. American Academy of Neurology, New York, April 1987. Neurology 37(Suppl 1):333, 1987.

54.     Luxenberg JS, Plato CC, Fox KM, Friedland RP, Rapoport SI. Dermatoglyphics in dementia of the Alzheimer type. American Academy of Neurology, New York, April 1987. Neurology 37(Suppl 1):333, 1987.

55.     Luxenberg JS, Swedo SE, Flament MF, Friedland RP, Rapoport J, Rapoport SI. Neuroanatomic abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. American Academy of Neurology, New York, April 1987. Neurology 37(Suppl 1):110, 1987.

56.     May C, Haber M, Young S, Tomai T, Gold P, Friedland RP. Osmoregulation in Alzheimer's Disease. American Academy of Neurology, New York, April 1987. Neurology 37(Suppl 1):166, 1987.

57.     Ober BA, Koss E, Delis DC, Jagust WJ, Friedland RP. Drawing performance in Alzheimer-type dementia and its relationship to brain glucose metabolism. International Neuropsychological Society, Washington, D.C. Journal of Clinical and Experimental Neuropsychology 9:80, 1987.

58.     Renfrew JW, May C, Tamarkin L, Friedland RP, Rapoport SI. Circadian rhythms in Alzheimer's disease, Society for Neuroscience, New Orleans, November 1987. Society for Neurosciences Abstracts 13(Part 2):1039, 1987.

59.     Luxenberg JS, Kaye J, Friedland RP, Rapoport SI. Serial quantitative CT in mild dementia of the Alzheimer type, American Geriatrics Society, Journal of the American Geriatrics Society, 1987.

top

60.     Luxenberg JS, Plato CC, Fox KM, Friedland RP, Rapoport SI. Digital and palmar dermatoglyphics in dementia of the Alzheimer type. International Congress of Anthropological and Ethnological Sciences, Zagreb, Yugoslavia, July 1988.

61.     Kaye JA, Morre AM, Friedland RP, Rapoport SI. Distinctive features of patients with dementia of the Alzheimer type and myoclonus. American Neurological Association, Philadelphia, PA, October 1988. Annals of Neurology 24:132-133, 1988.

62.     Kaye JA, DeCarli C, Tocchi L, Friedland RP. Basal forebrain hypointensites are increased in healthy aging, but not in Alzheimer's disease. Society of Magnetic Resonance in Medicine. San Francisco, August 1988.

63.     Koss E, Luxenberg J, Moore A, Friedland RP. Occupational exposure to toxins in Alzheimer's disease (AD): Metabolic and behavioral correlates. International Neuropsychological Society, New Orleans, LA, January 1988. Journal of Clinical and Experimental Neuropsychology 10:39, 1988.

64.     Kumar A, Friedland RP, Rapoport S. Metabolic studies in identical twins discordant for dementia of the Alzheimer type. Society of Biological Psychiatry. Montreal, April 1988.

65.     Berman KF, Schapiro MB, Friedland RP, Rapoport SI, Weinberger DR. Regional cerebral blood flow during cognitive activation in Down's syndrome. Society for Neuroscience, Toronto, October 1988. Society for Neuroscience Abstracts 14(Part 2):1012, 1988.

66.     DeCarli C, Kaye J, Levy LM, May C, Daly E, Friedland RP. MRI morphometry of the midbrain in Alzheimer's disease. Society of Magnetic Resonance in Medicine San Francisco, August 1988.

67.     DeCarli C, Kaye J, Levy LM, May C, Friedland. Quantitative analysis of midbrain structures in Alzheimer's disease using MRI. American Neurological Association. Philadelphia, October 1988. Annals of Neurology 24:133, 1988.

68.     Friedland RP, Koss E, Kumar A, Gaine S, Metzler D, Haxby JV, Moore A, Grady C, Rapoport SI. Motor vehicle accidents in dementia of the Alzheimer type. American Neurological Association. Philadelphia, October 1988. Annals of Neurology 24:133, 1988.

69.     Friedland RP, Luxenberg J, Koss E. A quantitative study of intracranial calcification in dementia of the Alzheimer type. Society for Neuroscience, Toronto, October 1988. Society for Neuroscience Abstracts 14(Part 2):101, 1988.

70.     Grady CL, Berg G, Carson RE, Daube-Witherspoon ME, Friedland RP, Rapoport SI. Quantitative comparison of glucose metabolic rates from two positron emission tomographs. Society of Nuclear Medicine, San Francisco, June 1988. Journal of Nuclear Medicine 29:867, 1988.

71.     Haxby JV, Grady CL, Horwitz B, Schapiro MB, Carson RE, Ungerleider LG, Mishkin M, Herscovitch P, Friedland RP, Rapoport SI. Mapping two visual pathways in man with regional cerebral blood flow (rCBF) as measured by positron emission tomography (PET) H2 150. Society for Neuroscience. Toronto, October 1988. Society for Neuroscience Abstracts 14(Part 1):750, 1988.

72.     Kumar A, Friedland RP, Rapoport S. Structural and neuropsychological studies in three identical twin paris discordant for dementia. Society of Biological Psychiatry. Montreal, April 1988.

73.     DeCarli C, Fugate L, Falloon J, Eddy J, Pizzo P, Friedland RP. Brain growth and cognitive improvement in children with human immunodeficiency virus-induced encephalopathy after 6 months of chronic infusion azidothymidine therapy. American Academy of Neurology, Chicago, 1989. Neurology 39(Suppl 1):186, 1989.

74.     DeCarli C, Teichberg D, Horwitz B, Friedland RP, Rapoport SI. A method for measurement of whole brain, temporal lobe, central and peripheral cerebral spinal fluid (CSF) volume from magnetic resonance image (MRI). American Academy of Neurology, Chicago, April 1989

75.     Friedland RP, Grady CL, Schapiro MB, Moore A, Kumar A, Kinsel V. Family history of dementia and regional cerebral glucose utilization (rCMRglc) in dementia of the Alzheimer type (AD). American Academy of Neurology, Chicago, April 1989. Neurology 39(Suppl 1):168, 1989.

76.     Friedland RP, Horwitz B, Grady C, DeCarli C, Schapiro MB, Kumar A, Rapoport SI. An ROC analysis of the diagnostic accuracy of PET with FDG and X-ray computed tomography in Alzheimer's disease. International Symposium on Cerebral Blood Flow and Metabolism, Bologna, May 1989.  Journal of Cerebral Flood Flow and Metabolism 9(Suppl 1):S566, 1989.

77.     Friedland RP and Raichle M. Co-Chairman and Speaker, Roundtable on functional and pharmacological activation studies of neurodegenerative disease using physiological imaging. International Symposium on Cerebral Blood Flow and Metabolism, Bologna, May 1989.

78.     Grady CL, Haxby JV, Horwitz B, Schapiro MB, Carson RE, Herscovitch P, Ungerleider LG, Mishkin M, Friedland RP, Rapoport SI. Mapping human visual systems for object recognition and spatial localization by measurement of regional cerebral blood flow. International Symposium on Cerebral Blood Flow and Metabolism, Bologna, June 1989. Journal of Cerebral Blood Flow and Metabolism 9(Suppl 1):S574, 1989.

79.     Grady CL, Haxby J, Schapiro MB, Kumar A, Friedland RP, Rapoport SI. Heterogeneity in dementia of the Alzheimer type (DAT): subgroups identified from cerebral metabolic patterns using positron emission tomography (PET). American Academy of Neurology, Chicago, April 1989. Neurology 39(Suppl 1):167-168, 1989.

80.     Kozachuk WE, Friedland RP, Aronin N, Marshall P. Magnetic resonance imaging (MRI) in familial inverted chorea (FIC). American Academy of Neurology, Chicago, April 1989. Neurology 39(Suppl 1):128, 1989.

81.     Kumar A, Schapiro MB, Grady C, Friedland RP, Rapoport SI. High resolution studies of cerebral glucose metabolism with 18-FDG PET in Alzheimer's Disease. Society of Nuclear Medicine, St. Louis, June 1989. Journal of Nuclear Medicine 30:771, 1989.

82.     Kumar A, Schapiro MB, Grady JV, Friedland RP, Ball MJ, Rapoport SI. Cerebral metabolic and structural studies in three pairs of identical twins discordant for Alzheimer's disease. Symposium on Familial Alzheimer's Disease, Seattle, May 1989. Alzheimer's Disease and Associated Disorders: An International Journal 3(Suppl 1):9, 1989.

83.     Kumar A, Schapiro MB, Grady CL, Friedland RP, Rapoport SI. Serial metabolic studies in twins discordant for dementia. American Psychiatric Association, San Francisco, May 1989.

84.     Schapiro MB, Kumar A, White B, Grady CL, Friedland RP, Rapoport SI. Alzheimer's disease (AD) in mosaic/translocation Down's Syndrome (DS) without mental retardation. American Academy of Neurology, Chicago, April 1989. Neurology 39(Suppl 1):169, 1989.

85.     Friedland RP, Iadecola C. Roy and Sherrington (1890): A centennial re-examination. American Academy of Neurology, Miami, April 1990. Neurology 40(Suppl 1):289, 1990.

86.     Pietrini P, Schapiro MB, Kozachuk W, Aronin N, Marshall P, Kumar A, Kaye JA, Friedland R, Rapoport SI. Cerebral glucose metabolism in familial inverted chorea assessed by PET. Society of Nuclear Medicine, Washington, DC, Journal of Nuclear Medicine 31:740-741, June 1990.

87.     Friedland RP. The cerebral circulation in Alzheimer's disease (AD): Model of a pathophysiological cascade. All Ohio Alzheimer's Disease Symposium, Columbus, Ohio, September 1990.

88.     Friedland RP, Marotta CA, Majocha RE, Reno JM, Lyle LR, Berridge M, Miraldi F. Anti-amyloid antibodies for in-vivo diagnosis of Alzheimer's disease. American Academy of Neurology, Cincinnati, April 1991. Neurology 41(Suppl 1):156, 1991.

89.     Friedland RP, Marotta CA, Majocha RE, Lyle LR, Reno JM, Miraldi F, Berridge MS. Anti-amyloid antibodies for in-vivo immunocytochemical studies of Alzheimer's disease using neuroimaging. International Symposium on Cerebral Blood Flow and Metabolism, Miami, June 1991. Journal of Cerebral Blood Flow and Metabolism 11(Suppl 2):S186, 1991.

top

90.     Lerner AJ, Koss E, Patterson M, Ownby RL, Chatterjee A, Friedland RP, Whitehouse P. Visual hallucinations in Alzheimer's Disease and the Behave-AD, American Academy of Neurology, San Diego, May 1992. Neurology 42(suppl 3): 140, 1992.

91.     Weinstein EA, Friedland RP, Wagner EE. Denial/unawareness of impairment in Alzheimer's Disease. American Academy of Neurology, San Diego, May 1992, Neurology 42(Suppl 3):200.

92.     Debanne SM, Rowland DV, Schnell A, Hedera P, Koss E, Lerner A, Smyth K, Whitehouse P, Friedland RP. Issues related to the selection of controls when exposure is related to diagnosis. World Federation of Neurology, Research Group on Neuroepidemiology, San Diego, May 1992, Neuroepidemiology 11(2):9, 1992.

93.     Smyth KA, Koss E, Neundorfer M, Friedland RP, Whitehouse PJ. Deficit awareness and denial in Alzheimer's disease. Third International Conference on Alzheimer's Disease and Related Disorders. Padova, July 1992.

94.     Lerner A, Friedland RP, Riley D, Whitehouse PJ, Lanska D, Vick N, Cochron E, Tresser N, Cohen M, Gambetti P. Dementia with pathologic findings of cortical basal ganglionic degeneration. American Neurological Association, Toronto, October 1992, Annals of Neurology 32:271, 1992.

95.     Friedland RP, Weinstein EA, Wagner EE. Frontal lobe hypometabolism is associated with denial of illness in Alzheimer's disease. Society of Neuroscience. Anaheim, October 1992, Society for Neuroscience Abstracts 1992; 18:735.

96.     Friedland RP, Reno JM, Majocha RE, Van Haight C, Lyle LR, Berridge MS, Miraldi F, Marotta CA. Development of a monoclonal antibody targeting the amyloid ß protein for immunochemical neuroimaging. American Academy of Neurology, New York, April 1993, Neurology 43:A213, 1993.

97.     Petot G, Debanne S, Hedera P, Koss E, Lerner AJ, Rowland D, Schnell A, Smyth K, Friedland RP. Use of a food frequency questionnaire in a risk factor study of Alzheimer's disease. World Federation of Neurology Research Group on Neuroepidemiology, New York, April 1993, Neuroepidemiology 12:135, 1993.

98.     Friedland RP, Smyth KA, Koss E, Schnell A, Lerner A, Hedera P, Petot G, Rowland D, Debanne S. Education and its surrogates as protective factors for Alzheimer's disease (AD): Design of a case-control study. World Federation of Neurology Research Group on Neuroepidemiology, New York, April 1993, Neuroepidemiology 12:124, 1993.

99.     Ford AB, Debanne SM, Friedland RP, Fitzgerald PA. Smoking and the incidence of dementia: A population based study. American Epidemiological Society, Pittsburgh, December 1992.

100.   Friedland RP, Reno JM, Majocha RE, Van Haight C, Lyle LR, Berridge MS, Miraldi F, Marotta CA. Immunochemistry of Alzheimer's disease: Development of a monoclonal antibody targeting the amyloid ß protein for neuroimaging. International Symposium on Cerebral Blood Flow and Metabolism, Sendai, Japan, May 1993. Journal of Cerebral Blood Flow and Metabolism 13:S244, 1993.

101.   Ben-Meir A, Bardenstein DS, Lee P, Friedland RP, Mulvihill P, Perry G. Tau protein, ubiquitin and amyloid precursor protein in the eyes of patients with Alzheimer disease (AD). Association for Research in Vision and Ophthalmology, Sarasota, Florida, April 1993.

102.   Lerner A, Cohen DL, Pax AB, Friedland RP, Kalaria RN. Cell adhesion molecules in the vascular and neocortical pathology of Alzheimer's disease. Society for Neuroscience, Washington DC, November 1993. Society for Neuroscience Abstracts 19:623, 1993.

103.   Hedera P, Lerner AJ, Stuckey J, Friedland RP. Acute confusional states in Alzheimer's disease. Society for Neuroscience, Washington, DC, November 1993. Society for Neuroscience Abstracts 19:229, 1993.

104.   Hedera P, Lai S, Haacke ME, Hopkins AL, Friedland RP, Friedman L. High resolution gradient echo functional imaging of visual cortex. Radiological Society of North America, Chicago, November 1993. Radiology, 189:140, 1993.

105.   Lai S, Haacke ME, Hopkins A, Wasserman B, Buckley P, Friedman L, Meltzer H, Hedera P, Friedland RP. High resolution 2D and 3D gradient-field-echo functional imaging correlated with high resolution MRA. Society for Magnetic Resonance in Medicine. Magnetic Resonance in Medicine p. 167, 1993.

106.   Hedera P, Lai S, Haacke EM, Hopkins AL, Friedland RP, and Friedman L. High resolution GRE functional imaging of visual cortex. Radiology, Volume 189, 140, 1993.

107.   Friedland RP (Chairman), Raskind M, Clarfield M. Symposium: The evaluation of the patient with dementia: Differential diagnosis and use of medical resources. American Geriatrics Society, May 1994, Los Angeles, Journal of the American Geriatrics Society (Abstract), 1994.

108.   Petot GJ, Debanne SM, Hedera P, Koss E, Lerner AJ, Rowland DY, Schnell AH, Smyth K, Friedland RP. Determination of diet patterns throughout adult life in a case control study of Alzheimer's disease. Nutritional Assessment of Elderly Populations: Measure and Function, United States Department of Agriculture, Boston, MA, October 1993.

109.   Hedera P, Lai S, Haacke EM, Lerner AJ, Hopkins AL, Lewin JS, Friedland RP. Localization of visual cortical activation using susceptibility sensitized MRI: studies in albinos and normal subjects. American Academy of Neurology, Washington, DC, May 1994, Neurology, 44(Suppl 2):A266, 1994.

110.   Lerner AJ, Strick N, Lowy M, Hedera P, Friedland RP. Altered hypothalamic-pituitary-adrenal axis responsivity in Alzheimer's disease. American Academy of Neurology, Washington DC, May 1994. Neurology (Abstract, in press), 1004.

111.   Rowland D, Debanne SM, Schnell A, Durand E, Koss E, Smyth KA, Whitehouse PJ, Friedland RP. The choice of respondent for controls in a case-control study where cases cannot self report. World Federation of Neurology: Research Group on Neuroepidemiology, Neuroepidemiology (Abstract, in press).

112.   Bardenstein DS, Friedland RP, Richey P, Harik S, Perry G. Immunocytochemical (ICC) localization of glucose transporter (GLUT-1) in the human eye. Association for Research in Vision and Ophthalmology, Sarasota, Florida, May 1994, Investigative Ophthalmology and Visual Science, 33:2085, 1994.

113.   Friedland RP, Reno JM, Majocha RE, Berridge MS, Miraldi F, Hedera P, Lyle LR, Marotta CA. Imaging studies of a TC-99 anti Aß Fab monoclonal antibody (MAB) in Alzheimer's disease (AD) using SPECT. Society for Neuroscience, November 1994, Miami Beach, Society for Neuroscience Abstracts 20:1057, 1994.

114.   Lai S, Hedera P, Haacke EM, Lerner AJ, Hopkins AL, Lewin JS, Friedland RP. Functional MRI: Promising approach for the evaluation of visual pathway abnormalities associated with albinism. Society of Magnetic Resonance, San Francisco, California, Journal of Magnetic Resonance Imaging, 4:59, 1994.

115.   Petot GJ, Debanne SM, Durand E, Hedera P, Koss E, Lerner AJ, Rowland DY, Schnell AH, Smyth K, Friedland RP. Diet Patterns During Adult Life a Case Control Study of Risk Factors for Alzheimer's Disease: Preliminary Data for Selected Nutrients and Food Groups. Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, July-August 1994. Neurobiology of Aging, 15, Suppl: S47, (Abstract), 1994.

116.   Friedland RP, Marotta CA, Lyle L, Reno J, Miraldi F, Berridge M, Kalaria R, Hedera P. Noninvasive Imaging Using a Murine Monoclonal Anti-Aß Antibody Fab Labeled with Technetium 99m in Alzheimer's Disease. Fourth International Conference on Alzheimer's Disease and Related Disorder, Minneapolis, July-August 1994. Neurobiology of Aging, 15, Suppl 1: S96-97, (Abstract), 1994.

117.   Koss E, Rowland DY, Debanne SM, Schnell AH, Porter C, Durand E, Hedera P, Lerner AJ, Petot GJ, Smyth K. Relationships Between Past Cigarette Smoking Status and Cognitive Functions in Healthy Aging. Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, July-August 1994. Neurobiology of Aging, 15 Supp, S47 (Abstract), 1994.

118.   Petot GJ, Debanne SM, Durand E, Hedera P, Koss E, Lerner AJ, Rowland DY, Schnell AH, Smyth K, Friedland RP. Adaptation of the Block Food Frequency Questionnaire to Obtain Adult Life-Time Dietary patterns from Alzheimer's Patients' Surrogates, Controls and Controls' Surrogates. Second International Conference on Dietary Assessment Methods (Abstract), 1994.

119.   Friedland RP, Kalaria RN. Alzheimer's Disease and Related Disorders Research in the Developing World and Eastern Europe - Workshop. Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, August 1994.

top

120.   Lewin JS, Friedman L, Wu D, Miller DA, Thompson LA, Klein SK, Hedera P, Buckley P, Friedland RP, Meltzer. Localization of human sustained attention neural networks: detection with functional MR using a visual vigilance paradigm Proceedings of the Society for Nuclear Magnetic Resonance (Abstract, in press).

121.   Lerner A, Hedera P, Koss E, Stuckey J, Friedland RP. Acute confusional states in Alzheimer's disease. First World Congress on Stress, NIH, Bethesda, October 1994.

122.   Lai S, Hedera P, Haacke EM, Lewin J, Wu D, Friedland RP. Effects on Acetazolamide on Cerebral Blood Flow in Normal Humans as Assessed with T2^*. weighted MR Imaging at 1.5-T: Preliminary Results. Society for Magnetic Resonance. Proceedings of the Society of Magnetic Resonance, San Francisco, p. 699, August 1994.

123.   Koss E, Elshaw E, Salipante E, Rowland D, Cole R, Friedland RP, Whitehouse PJ, Smyth KA, Petot G, Hedera P, Esteban-Santillan C, Debanne S. Positive relationship between practicing a musical instrument and IQ scores in older healthy adults. World Federation of Neurology Research Group on Neuroepidemiology, Seattle, May 1995, Neuroepidemiology, 14;18, (Abstract), 1995.

124.   Lerner A, Cole R, Debanne S, Esteban-Santillan E, Hedera P, Koss E, Friedland RP, Whitehouse PJ, Smyth KA, Rowland D, Petot G. Immunological and endocrine conditions in an Alzheimer's disease case-control study. World Federation of Neurology Research Group on Neuroepidemiology, Seattle, May 1995, Neuroepidemiology, 14;12, (Abstract), 1995.

125.   Friedland RP, Smyth KA, Koss E, Esteban-Santillan E, Cole R, Lerner AJ, Hedera P, Durand E, Petot G, Rowland DY, Debanne S. Persons with Alzheimer's disease (AD) engage in fewer premorbid stimulating activities than controls: Results from a case-control study. World Federation of Neurology Research Group on Neuroepidemiology, Seattle, May 1995, Neuroepidemiology, 14:8, (Abstract), 1995.

126.   Petot GJ, Feinstein S, Cole R, Debanne S, Koss E, Lerner AJ, Rowland DY, Smyth K, Whitehouse PJ, Friedland RP. Preliminary data on diet patterns throughout adult life in a case control study of risk factors for Alzheimer's disease. World Federation of Neurology Research Group on Neuroepidemiology, Seattle, May 1995, Neuroepidemiology, 14:7-8, (Abstract), 1995.

127.   Marotta CA, Friedland RP, Muswick G, Nelson D, Berridge MS, Miraldi F, Hedera P, Lyle L, Reno J, Majocha R. Imaging studies with murine anti Aß monoclonal antibody (MAB) Fab 10H3 in Alzheimer's disease (AD) patients. American  Academy of Neurology, May 1995, Seattle. Neurology 45(Suppl 4): A405, (Abstract), 1995 

128.   Friedland RP, Kalaria RJ. Alois Alzheimer, Willibald Scholz and the history of cerebrovascular pathology in Alzheimer's disease. Society for Neuroscience, San Diego, November 1985, Society for Neuroscience Abstracts, 21(1):247, 1995.

129.   Petot GJ, Feinstein SJ, Cole R, Debanne SM, Koss E, Lerner AJ, Rowland  DY, Smyth K, Whitehouse PJ, Friedland RP. Preliminary data on diet patterns throughout adult life in a case-control study of risk factors for Alzheimer's disease. World Federation of Neurology, Research  Group on Neuroepidemiology, 14:6-7 (Abstract), 1995.

130.   Friedland RP, Smyth KA, Koss E, Esteban-Santillan C, Cole R, Lerner AJ, Hedera P, Durand E, Petot G, Rowland DY, Debanne S. Persons with Alzheimer's disease (AD) engage in fewer premorbid stimulating activities than controls: Results from a case control study. World Federation of Neurology, Research Group on Neuroepidemiology, Neuroepidemiology , 14:8 (Abstract), 1995.

131.   Lerner AJ, Cole R, Debanne S, Esteban-Santillan C, Hedera P, Koss E, Petot G, Rowland D, Smyth K, Whitehouse PJ, Friedland RP. Immunological and endocrine conditions in an Alzheimer's disease case-control study. World Federation of Neurology, Research Group on Neuroepidemiology, Neuroepidemiology, 14:10 (Abstract), 1995.

132.   Koss E, Elshaw E, Salipante E, Rowland D, cole R, Debanne S, Esteban-Santillan C, Hedera P, Lerner AJ, Petot G, Smyth KA, Whitehouse PJ, Friedland RP. Positive relationship between playing a musical instrument and IQ scores in older healthy adults. World Federation of Neurology, Research Group on Neuroepidemiology, Neuroepidemiology, 14:13 (Abstract), 1995 

133.   Esteban-Santillan C, Smyth KA, Conaway C, Rowland D, Debanne S, Koss E, Lerner A, Petot G, Whitehouse PJ, Friedland RP. Mental, social and physical demands of jobs as risk factors for Alzheimer's disease, American Academy of Neurology, March 1996, San Francisco. Neurology : 46(2 suppl)A433-434. (Abstract), 1996

134.   Sauer S, Bardenstein DS, Friedland RP, Perry G.  Immunohistochemical detection of increased facilitative glucose transporter-1 expression in corneal endothelial stress. Association for Research in Vision and Ophthalmology, Sarasota, May 1996, Investigative Ophthalmology and Visual Science 37:S86 (Abstract), 1996.

135.   Friedland RP, Smyth K, Esteban-Santillan C, Koss E, Cole R, Lerner AJ, Strauss M, Whitehouse PJ, Petot G, Rowland DY, Debanne S.  Premorbid environmental complexity is reduced in patients with Alzheimer’s disease (AD) as compared to age and sex matched controls: Results of a Case-Control Study.  Fifth International Conference on Alzheimer’s Disease and Related Disease, Osaka, July 1996. Neurobiology of Aging, 17:S122, (Abstract), 1996.

136.   O’gengo JA, Sayi JG, Cohen DL, Matuja WB, Kitinya J, Kimani JK, Friedland RP, Kalaria RN.  Brain amyloid ß deposition in non-demented african subjects from East Africa. Fifth International Conference on Alzheimer’s Disease and Related Disease, Neurobiology of Aging, 17:S123, (Abstract), 1996.

137.   Sayi JG, Premkumar DRD, Patel NB, Bhandari AS, Gatere S, Matuja WB, Friedland RP, Koss E, Kalaria RN.  Apolipoprotein E alleles in elderly East Africans. Society for Neuroscience, Washington DC, November, 1996, Society for Neuroscience Abstracts, 22:207, 1996.

138.   Muzic RF, Berridge MS, Friedland RP, Zhu N, Miraldi F.  PET measurement of nicotine receptor binding. Society of Nuclear Medicine 43rd annual meeting, Denver, June 1996. Journal of Nuclear Medicine Abstract, 37:11, (Abstract), 1996.

139.   Petot GJ, Cole R, Debanne SM, Koss E, Lerner AJ, Rowland DJ, Smyth K, Whitehouse PJ, Friedland RP.  Adult lifetime dietary intake patterns of antioxidant nutrients and foods in a case control study of risk factors for Alzheimers’ Disease: Preliminary data.  World Federation of Neurology - Research Group on Neuroepidemiology, San Francisco, March, 1996, Neuroepidemiology 15: p.13, (Abstract), 1996.

140.   Rowland DY, Whitehouse PJ, Rossor M, Roques P, Debanne SM, Koss E, Lerner A, Petot G, Friedland RP, Smyth K.  Influences on the expression of autosomal-dominant Alzheimer’s disease: Comparison of methods to analyze environmental factors.  World Federation of Neurology. Research Group on Neuroepidemiology, San Francisco, March, 1996, Neuroepidemiology 15: p.18, (Abstract), 1996 

141.   Petot G, Debanne S, Smyth K, Rowland D, Koss E, Lerner A, Cole R, Friedland RP.  Adult lifetime dietary patterns of antioxidant vitamin and carotenoid consumption in a case control study of risk factors for Alzheimer’s disease. American Aging Association, San Francisco, October 1996. 

142.   Friedland RP, Kalaria RN, Marotta CA..  Prospects for non-invasive imaging of amyloid ß protein in Alzheimer’s disease. Symposium on Neurodegenerative Disorders: Common Molecular Mechanisms, Ocho Rios, Jamaica, February 1997.

143.   Bowriratt A, Korczyn A, Kahana E, Friedland RP. Prevalence of dementia of the Alzheimer’s type in an elderly Arab population: A door to door survey.  Alzheimer’s Disease International,  Twelfth International Conference.  Jerusalem, October 1996.

144.   Friedland RP.  Denial of Illness in Alzheimer’s Disease. Alzheimer’s Disease International: 12th International Conference, Jerusalem, October 1996.

145.   Friedland RP, Kalaria RN, Marotta CA.  Neuroimaging of vessel amyloid in Alzheimer’s disease.  Cerebrovascular pathology in Alzheimer’s Disease. New York Academy of Sciences, East Rutherford, New Jersey, November 1996.

146.   Lerner AJ, Koss E, Gilham S, Cole R, Debanne S, Esteban-Santillan C, Petot G, Rowland DY, Smyth KA, Whitehouse PJ, Friedland RP. Estrogen replacement therapy as a protective factor for Alzheimer disease: Interactions with other risk factors. Society for Neuroscience, Washington DC, November 1996, Society for Neuroscience, Vol. 22, p.15 (Abstract), 1996.

147.   O’gengo JA, Cohen DL, Sayi JG, Matuja WB, Kitinya JN, Kimani JK, Friedland RP, Kalaria RN.  Amyloid ß protein deposition in brains of non-demented East Africans. Society for Neuroscience, Washington DC, November 1996.  Society for Neuroscience Abstracts Vol. 22, 1173, 1996 

148.   Friedland RP, Smyth K, Esteban-Santillan C, Koss E, Cole R, Lerner AJ, Strauss M, Whitehouse PJ, Petot G, Rowland DY, Debanne S.  Premorbid environmental complexity is reduced in patients with Alzheimer’s disease (AD) as compared to age and sex matched controls: Results of a Case-Control Study.  Proceedings of the Fifth International Conference on Alzheimer’s Disease and Related Disease, (K. Iqbal, B. Winblad, H. Wisniewski, Eds) Neurobiology of Aging, John Wiley and Sons, New York, in press.

149.   Bowirrat A, Treves T, Friedland RP, Korczyn AD.  Prevalence of dementia of Alzheimer’s type in Arab community in Israel World Federation of Neurology Research Group on Neuroepidemiology, Boston, April, 1997, (Dr. Bowirrat won the 1997 Bruce Schoenberg Award from the American Academy of Neurology for this paper), April 1997.

top

150.   Friedland RP, Lerner AJ, Smith AL, Huang SL, Siedlak S, Perry G.  Latent infection with cytomegalovirus in Alzheimer’s disease (AD).  Serum antibody and immunocytochemical studies.  Society for Neuroscience, New Orleans, October 1997.  Society for Neuroscience Abstracts 23 (Part I): 563, 1997.

151.   Friedland RP, Hall K, Unverzagt F, Hendrie H, Kalaria RN, Patel N, Gatere S, Bowirrat A, Korczyn A. Cross-Cultural Studies of Alzheimer’s disease in Africa and Israel.  Neurodegenerative Disorders: Common Molecular Mechanisms, Jamaica, February 1998.

152.   Koss E, Cole R, Gilmore GC, Debanne SM, Lerner AJ, Petot G, Riedel T, Smith A, Smyth KS, Strauss ME, Teel W, Whitehouse PJ, Friedland RP.  Relations between cognition and personality in healthy older adults.International Conference on Alzheimer’s Disease and Associated Disorders, Amsterdam, July 1998, Neurobiology of Aging, 19(4S):S13, 1998 

153.   Friedland RP.  Prospects for neuroimaging in early diagnosis and monitoring of therapy of Alzheimer’s disease.   International Conference on Alzheimer’s Disease and Associated Disorders, Amsterdam, July1998. Neurobiology of Aging, (Abstract), in press. 

154.   Friedland RP, Bowirrat A, Treves T, Chapman J, Korczyn AD.  Alzheimer’s disease prevalence is high in Israeli Arabs.  International Conference on Alzheimer’s Disease and Associated Disorders, Amsterdam, July 1998, Neurobiology of Aging, 19(4S): S139, 1998. 

155.   Petot GJ, Riedel TM, Cole R, Debanne SM, Koss E, Lerner AJ, Smyth KA, Whitehouse PJ, Friedland RP. Long term dietary intake patterns influence the development of Alzheimer’s disease in a Case Control study of lifestyle risk factors. International Conference on Alzheimer’s Disease and Associated Disorders, Amsterdam, July 1998. Neurobiology of Aging 19:45, S27, (Abstract), 1998.

156.   Teel WB, Farrer LA, Cupples LA, Debanne SM, Koss E, Lerner AJ, Rowland DY, Smith AL, Cole R Friedland RP, Duration of survival after onset of Alzheimer’s disease is not affected by cigarette smoking status in two epidemiologic studies. International Conference on Alzheimer’s Disease and Associated Disorders, Amsterdam, July 1998, Neurobiology of Aging 19(4S):S26, 1998.

157.   Teel WB, Farrer LA, Cupples LA, Debanne SM, Koss E, Lerner AJ, Rowland DY, Smith AL, Cole R Friedland RP, Duration of survival after onset of Alzheimer’s Disease is not affected by cigarette smoking status in two epidemiologic studies World Federation of Neurology Research Group on Neuroepidemiology, Minneapolis, May, Neuroepidemiology 17, 1998. 

158.   Bowirrat A, Treves T, Friedland, RP, Korcczyn AD.  Illiteracy is a risk factor for Alzheimer’s disease among Arab elderly in Israel. American Academy of Neurology, Minneapolis, April 1998, Neurology 50:A229, April 1998. 

159.   Friedland RP, Bowirrat A, Treves T, Chapman J, Korczyn AD.  The prevalence of dementia of Alzheimer type (DAT) is high in Israeli Arabs. Society of Neuroscience 1998, Society for Neuroscience Abstracts 24:257, 1998. 

160.   Smith AL, Cole R, Smyth KA, Koss E, Lerner AJ, Rowland DY, Debanne SM, Petot GJ, Teel WB, Friedland RP.  Protective effects of physical exercise on the development of Alzheimer’s disease. Neurology, 50, A90, 1998 (Abstract).

161.   Friedland RP. Genetic and environmental risk factors for Alzheimer’s disease in Kenya and Israel.  Neuroscience in Developing Countries: Getting Around the Problems, Society for Neuroscience Workshop, November 1998, Los Angeles, International Journal of Neuroscience 99:19, 1999.

162.   Bowirrat A, Friedland RP, Chapman J, Korczyn, AD. The very high prevalence of Alzheimer’s disease in an Arab population is not explained by apolipoprotein E e4 allele frequency.  American Academy of Neurology Annual Meeting, Toronto, April, 1999, Neurology 52(Suppl) A297, (Abstract), 1999.

163.   Friedland RP.  Prospects for noninvasive imaging of brain amyloid in Alzheimer’s disease Vascular factors in Alzheimer’s Disease, International Meeting, Northumberland, UK, May 1998.  Alzheimer Reports 2(S1): p.S27, 1999.

164.   Shi J, Perry G, Friedland RP, Siedlak S, Lamanna J.  Basic fibroblast growth factor and serum amyloid P component binding to amyloid deposits in a transgenic animal model overexpressing ß-amyloid: Evidence for the integrity of the blood-brain barrier.  Society for Neuroscience Annual Meeting, Miami Beach, October 1999.  Society for Neuroscience Abstracts 25(2): 1860, 1999. 

165.   Bowirrat A, Treves T, Chapman J, Friedland RP, Korczyn A. Alzheimer’s disease in an Israeli Arab village.  Fifth Tel Aviv University Alzheimer’s Disease Conference. June 1998.

166.   Bowirrat A, Friedland RP, Chapman J, and Korczyn AD.   The very high prevalence of Alzheimer’s disease in an Arab population is not explained by apolipoprotein allele frequency. World Federation of Neurology Neurogenetics Research Group, Toronto, April 1999.

167.   Bowirrat A, Friedland RP, Chapman J, and Korczyn AD. The frequency of the APO-e4 allele in Arab population in Israel.  World Federation of Neurology, Research Group on Neuroepidemiology, Toronto, April 1999 

168.   Bowirrat A, Friedland RP, Chapman J, and Korczyn AD. Alzheimer’s disease in Israeli Arabs. The First National Conference on Health Issues in the Arab-American Community, Dearborn, Michigan, April 1999.

169.   Baldwin C, Bowirrat A, Korczyn AD, Farrer L, Friedland RP. Increased Prevalence of Alzheimer’s Disease in an Arab-Israeli Community.  American Society for Human Genetics, San Francisco, October, 1999, American Journal of Human Genetics,65:A263, (Abstract),1999. 

170.   Kalaria RN, Patel NB, Kariuki M, Kioy P, Gatere S, Hall KS, Unverzagt FW, Hendrie HC, Friedland RP. Epidemiological studies and genetic factors in Alzheimer’s disease in rural Kenya.   Society of Neuroscientists of Africa 4th International Congress, Dakar, Senegal, April1999.

171.   Koss E, Cook TB, Cole R, Debanne SM, Petot GJ, Lerner AJ, Smyth KA, Friedland RP. Occupational lead exposure is a risk factor for Alzheimer’s disease: A case-control study. The Role of Human Exposure in the Prevention of Environmental Disease, Washington, DC,  September, 1999, National Institute for Environmental health Sciences.

172.   Lerner AJ, Mizrahi E, Chen C, Eckman C, Younkin S, Siavalas L, Koss  E, Petot G, Smyth KA, Debanne S, Cook T, Elston R, Friedland RP. Relationship of plasma amyloid beta fragments to serum cholesterol, high density lipoprotein, albumin and apolipoprotein E genotype.  American Academy of Neurology 52nd Annual Meeting Program, San Diego, May 2000, Neurology 54 (suppl. 3), p. A366, April 2000.

173.   Friedland RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, Petot G, Debanne SM.  Participation in non-occupational activities in midlife is protective against the development of Alzheimer’s disease: Results from a Case-Control study.  American Academy of Neurology, San Diego, April 2000, Neurology 54(suppl. 3), p. A360, 2000.

174.   Baldwin C, Korczyn AD, Bowirrat A, Friedland RP, Farrer L. Identification of a novel genetic locus for  Alzheimer’s disease and age associated memory impairment in an Arab-Israeli community. American Academy of Neurology, San Diego, April 2000, Neurology 54(suppl 3), p. A428, 2000.

175.   Koss E, Cook TB, Cole R, Debanne SM, Petot GJ, Lerner AJ, Smyth KA, Friedland RP. Occupational lead exposure is a risk factor for Alzheimer’s disease American Academy of Neurology, San Diego, April 2000, Neurology 54(suppl. 3), p. A361, 2000.

176.   Friedland RP. Implications of evolutionary biology of our understanding of neurodegenerative disease.  Regional North American Annual Meeting of the World Federation of Neurology -  Research Group on Neuroepidemiology, San Diego, May 2000, Neuroepidemiology (Abstract, in press).

177.   Chen C, Elston RC, Patel NB, Gatere  S, Kalaria RN, Friedland RP. Pilot study of a screening test for cognitive impairment for use in an East African population.  Regional North American Annual Meeting of the World Federation of Neurology -  Research Group on Neuroepidemiology, San Diego, May 2000, Neuroepidemiology (Abstract, in press).

178.   Bowirrat A, Friedland RP, Korczyn AD. Incidence of Alzheimer’s type dementia in an elderly Arab population. Regional North American Annual Meeting of the World Federation of Neurology -  Research Group on Neuroepidemiology, San Diego, May 2000, Neuroepidemiology (Abstract, in press).

179.   Friedland RP, Kalaria RN, Korczyn A, Farrer L. Update on the role of apolipoprotein E in Alzheimer’s disease.  6th Annual Symposium on Neurodegenerative Disorders: Common molecular mechanisms, Tobago,  April 2000, Journal of Alzheimer’s Disease (Abstract in press).

top

180.   Mizrahi E, Jacobsen D, Lerner AJ, Cook T, Soas A, Petot G, Koss E, Chen C, Friedland RP. Plasma homocysteine (tHcy) and dietary vitamin B6 and folic acid in Alzheimer’s disease (AD) and healthy aging. Society for Neuroscience New Orleans, November 2000, Society for Neuroscience Abstracts 26:1827,2000.

181.   Shi J, Perry G, Berridge MS, Aliev G, Smith M, LaManna J, Friedland RP.  Labeling of cerebral amyloid ß deposits in vivo using nasally administrated basic fibroblast growth factor (bFGF). Society for Neuroscience New Orleans, November 2000, Society for Neuroscience Abstracts 26:294, 2000.

182.   Friedland RP. Teaching critical thinking to medical students: How do doctors and scientists make decisions? Society for Neuroscience New Orleans, November 2000, Society for Neuroscience Abstracts (Abstract in press).

183.   Friedland RP, Fritsch T, Smyth K, Koss E, Lerner AJ, Chen C, Petot G, Debanne S. Participation in nonoccupational activities in midlife is protective against the development of Alzheimer’s disease: Results from a case control study. American Academy of Neurology 52nd Annual Meeting Program, San Diego, May 2000, Neurology 54 (suppl. 3), p. A360, April 2000.

184.   Koss E, Cook T, Cole R, Debanne S, Lerner AJ, Petot G, Smyth K, Friedland RP. Occupational lead exposure is a risk factor for Alzheimer’s disease: A case-control study. American Academy of Neurology 52nd Annual Meeting Program, San Diego, May 2000, Neurology 54 (suppl. 3), p. A361, April 2000.

185.   Baldwin C, Bowirrat A, Korczyn A, Farrer L, Friedland RP. Identification of a novel genetic locus for Alzheimer disease and age-associated memory impairment in an Arab-Israeli community.  American Academy of Neurology 52nd Annual Meeting Program, San Diego, May 2000, Neurology 54 (suppl. 3), p. A428, April 2000.

186.   Aliev  G, Shi J, LaManna J,  Friedland RP, Lamb BT. Mitochondria abnormalities mark vulnerable neurons in a YAC transgenic mice overexpression of amyloid ß.  World Alzheimer Congress 2000, Washington DC, July 2000, Neurobiology of Aging 21:S267, 2000.

187.   Aliev G, Shi J, LaManna J, and Friedland RP. The presence of atherosclerotic-like changes of the vascular wall in transgenic mice overexpressing amyloid ß.  World Alzheimer Congress 2000, Washington DC, July 2000 Neurobiology of Aging 21:S267, 2000.

188.   Farrer L, Baldwin C, Korczyn A, Bowirrat A, Friedland RP. Genetic linkage studies of Alzheimer’s disease in Israeli Arabs. World Alzheimer Congress 2000, Washington DC, July 2000 Neurobiology of Aging 21:S128, 2000.

189.   Friedland RP, Fritsch T, Smyth K, Koss E, Lerner AJ, Chen C, Petot G, Debanne S. Intellectual and physical activities are protective against the development of Alzheimer’s disease. World Alzheimer Congress 2000, Washington DC, July 2000 Neurobiology of Aging 21:S99, 2000.

190.   Mizrahi E, Fritsch T, Geldmacher D, Friedland RP, Lerner AJ. Medication utilization in  Alzheimer’s disease and healthy aging: Results in a research registry. World Alzheimer Congress 2000, Washington DC, July 2000 Neurobiology of Aging 21:S26, 2000.

191.   Koss E, Fritsch T, Rogus C, Friedland RP, Lerner AJ, Mizrahi E, Siavalis E, Smyth K. Risk factors for cognitive decline in healthy older adults. World Alzheimer Congress 2000, Washington DC, July 2000 Neurobiology of Aging 21:S33, 2000.

192.   Petot G, Cook T, Chen C, Riedel T, Debanne S, Koss E, Lerner AJ, Friedland RP. A high fat diet during adulthood increases risk for Alzheimer’s disease for those with the ApoE-4 allele. World Alzheimer Congress 2000, Washington DC, July 2000 Neurobiology of Aging 21:S246, 2000.

193.   Cook T, Lerner AJ, Mizrahi E, Siavalas E, Friedland RP, Koss E.  Increased risk for Alzheimer’s disease among women whose spouses engaged in lead-related activities. World Alzheimer Congress 2000, Washington DC, July 2000 Neurobiology of Aging 21:S246, 2000.

194.   Patel NB, Kalaria RN, Kioy P, Kariuki M, Hall K, Unverzagt F, Hendrie H, Gatere S, Friedland RP. High ApoE 4 allele frequencies in elderly Kikuyus in Kenya. World Alzheimer Congress 2000, Washington DC, July 2000 Neurobiology of Aging 21:S64, 2000.

195.   Lerner AJ, Mizrahi E, Chen C, Eckman C, Younkin S, Siavalas EL, Koss E, Petot G, Smyth KA, Debanne SM, Cook T,  Elston R, Friedland RP.  Relationship of plasma amyloid beta fragments to serum cholesterol, HDL, albumin and ApoE genotype.  World Alzheimer Congress 2000, Washington DC, July 2000 Neurobiology of Aging 21:S155, 2000.

196.   Aliev G, Shi J, Perry G, Lamb B, La Manna J, Friedland RP Neuronal mitochondrial abnormalities in yeast artificial chromosome transgenic mice overexpressing amyloid precursor protein. Society for Neuroscience, New Orleans, November 2000, Society for Neuroscience Abstracts 26:804, 2000.

197.   Mizrahi EH, Jacobsen DW, Lerner AJ, Cook TB, Soas AH, Petot GJ, Koss E, Chen CH, Kapur V, Friedland RP. Plasma total homocysteine and dietary vitamin B6 and folic acid in Alzheimer’s disease and healthy aging. Society for Neuroscience, New Orleans, November 2000, Society for Neuroscience Abstracts 26: 1827, 2000.

198.   Shi J, Perry G, Berridge MS, Aliev G, Smith MA, LaManna JC, Friedland RP. Labeling of cerebral amyloid Beta deposits in vivo using nasally administered basic fibroblast growth factor,  Society for Neuroscience, New Orleans, November, 2000, Society for Neuroscience Abstracts 26: 1827, 2000.

199.   Smith MA, Nunomura A, Sayre LM, Rottkamp CA, Zhu X, Raina AK, Hirai K, Friedland RP, Shi J, Aliev G, Wataya T, Shimohama S, Atwood CS, Perry G. Fundamental role of oxidative stress and stressors in Alzheimer’s disease. Dementia 14:232, 2000.

200.   Fritsch T, McClendon MJ, Smyth KA, Koss E, Lerner AJ, Chen CH, Petot G, Debanne SM, Friedland RP. The relationships between ethnicity, gender, education, occupational status and age at symptom onset in Alzheimer’s disease. The Gerontologist 40:145, 2000.

201.   Bowirrat A, Friedland RP, Korczyn A. Genetic analysis of dementia of the Alzheimer type among an elderly Arab population in Wadi Ara. World Federation of Neurology Research Group in Neuroepidemiology, Philadelphia, May 2001. Neuroepidemiology (abstract, in press)

202, Mizrahi EH, Bowirrat A, Korczyn AD, Jacobsen DW, Traore F, Petot GJ, Soas AH, Lerner AJ, Chen CH, Friedland RP. Homocysteine metabolism in Alzheimer’s disease patients and healthy controls in north America and Israel. Society for Neuroscience, November 2001, Society for Neuroscience Abstracts (in press).

203, Smith MA, Petot G, Nunomura A, Takeda A, Hirai K, Atwood CS, Friedland RP, Perry G. The role of oxidative stress and dietary modulation in Alzheimer’s disease. Presented at :Diet and Optimum Health, Portland, OR, May 2001.

204, Soas AH, Bowirrat A, Korczyn AD, Baldwin C, Farrer LA, Friedland RP. High prevalence of Alzheimer disease (AD) and low apolipoprotein E e4 allele frequency in an Arab population in Wadi Ara. Tenth Saudi Neurosciences Symposium, Riyadh, November 2000.

205. Bowirrat A, Friedland RP, Korczyn AD. Incidence of Alzheimer-Type dementia among elderly Arab subjects with age related cognitive decline (ARCD) in Wadi Ara. American Academy of Neurology, Philadelphia, April 2001, Neurology 56:A184, 2001.

206. Friedland RP, Farrer LA, Soas AH, Debanne SM, Petot GJ, Traore F, Bowirrat A, Jacobsen DW, Launer L, Chen C, Korczyn AD. Gene-environment interactions and the causal web of Alzheimer’s disease. The First International Symposium on Alzheimer’s Disease in the Middle East, Limassol, Cyprus, April 2001.

207. Bshara O, Bowirrat A, Friedland RP, Korczyn AD.  Comparison of the diagnoses of dementia in the Wadi Ara study. The First International Symposium on Alzheimer’s Disease in the Middle East, Limassol, Cyprus, April 2001.

208. Baldwin CT, Bowirrat A, Farrer, Waraska K, Korczyn AD, Friedland RP. Molecular genetic studies of Alzheimer disease in the Middle East. The First International Symposium on Alzheimer’s Disease in the Middle East, Limassol, Cyprus, April 2001.

209. Treves Tam Bowirrat A, Friedland RP, Korczyn AD, Schooling and smoking in dementia. The First International Symposium on Alzheimer’s Disease in the Middle East, Limassol, Cyprus, April 2001.

210. Bowirrat A, Friedland RP, Korczyn AD, Epidemiology of dementia of the Alzheimer type among an elderly Arab population in Israel, The First International Symposium on Alzheimer’s Disease in the Middle East, Limassol, Cyprus, April 2001..

211. Farrer LA, Bowirrat A, Friedland RP, Waraska K, Adams JC, Korczyn A, Baldwin CT. Identification of multiple loci for Alzheimer’s disease in an Israeli-Arab community. American Society for Human Genetics, San Diego, October 2001, American Journal of Human Genetics (abstract, in press)

212. Farrer LA, Friedland RP, Baldwin C, Waraska K, Korczyn A, Bowirrat A. Genetic studies of unique ethnic populations. The Latest Links: Genes and Alzheimer’s Disease, National Institute on Aging Symposium, San Diego, November 2001.

213. Arvanitakas Z, Lucas JA, Lerner AJ, Friedland RP, Younkin LH, Younkin SG, Graff-Radford NR. Amyloid beta protein plasma levels correlate with serum cholesterol parameters in Apo E4 negative Alzheimer’s disease patients and controls. American Neurological Association, Annual Meeting, Annals of Neurology (Abstract in press).

214. Bowirrat A, Friedland RP, Korczyn AD. Incidence of dementia among the elderly Arab population in Wadi Ara, Israel. American Academy of Neurology, Denver, April, 2002.  Neurology 58:A273, (Abstract).

215. Bowirrat A, Friedland RP, Korczyn AD. Vascular dementia among elderly Arbs in Wadi Ara. Second International Congress on Vascular Dementia, Salzburg, February, 2002.

216.  Farrer, L, Bowirrat, A, Friedland, R, Waraska, K, Korczyn, A, Baldwin, C.  Identification of multiple loci for Alzheimer disease in an inbred Israeli-Arab community.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S425, Abstract No.1558, 2002.

217.  Bowirrat, A, Friedland, R, Farrer, L.  Incidence of Alzheimer’s disease in an elderly Arab population in Wadi Ara, Israel.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S328, Abstract No. 1220, 2002.

218.  Friedland, R, Bowirrat, A, Farrer, L, Korczyn, A.  Vascular dementia (VaD) among elderly Arabs in Wadi Ara.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S54, Abstract No. 208, 2002.

219.  Korczyn, A, Bowirrat, Friedland, R.  Mortality from dementia of Alzheimer type (DAT) among elderly Arabs in Wadi Ara.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S300, Abstract No. 1118, 2002.

220.  Shi, J, Perry, G, Berridge, M, Aliev, G, Smith, M, LaManna, J, Kuniyoshi, S, Friedland, R.  In vivo labeling of cerebral amyloid-beta deposits using intranasal BFGF and SAP in a transgenic mouse model.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S276, Abstract No. 1032, 2002.

221.  Petot, G, Debanne, S, Traore, F, Fritsch, T, Lerner, A, Smyth, K, Friedland, R.  Dietary patterns during mid-adult life and risk for Alzheimer’s disease.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S301, Abstract No. 1124, 2002.

222.  Aliev, G, Perry, G, Seyidova, D, Lamb, B, Neal, M, Siedlak, S, Smith, M, LaManna, J, Friedland, R.  The role of mitochondria failure in the development of ad-like pathology in an aged transgenic mouse model of AD.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S415, Abstract No. 1525, 2002.

223.  Friedland, R, Petot, Grace.  Dietary recommendations for Alzheimer’s disease: an evolutionary perspective.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S6, Abstract No. 20, 2002.

224.  Debanne, S, Traore, F, Petot, G, Fritsch, T, Lerner, A, Rowland, D, Friedland, R.  The presence of the apoliproprotein E-e4 allele modifies the association between Alzheimer’s disease and smoking.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S296, Abstract No. 1106, 2002.

225.  Petot, G, Traore, F, Debanne, S, Fritsch, T, Lerner, A, Smyth, A, Friedland, R.  Dietary fat intake in mid-adulthood and  apoliproprotein E genotype as risk factors for Alzheimer’s disease.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S297, Abstract No. 1107, 2002.

226.  Mizrahi, E, Bowirrat, A, Korczyn, A, Jacobsen, D, Traore, F, Petot, G, Lerner, A, Debanne, S, Aundsky, A, Friedland, R.  Plasma total homocysteine, vitamin B12 and folate levels in Alzheimer’s disease and healthy aged controls in Arabs residing in Israel.  8^th Annual International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, Sweden, July, 2002, Neurobiology of Aging 23(1S), S304, Abstract No. 1135.

227. Bowirrat A, Friedland RP, Korczyn AD. Vascular dementia among elderly Arabs in Wadi Ara. Ninth Tel Aviv University Alzheimer’s Disease Conference, Israel, June 2002.

228.  Aliev, G, Perry, G, Seyidova, D, Lamb, BT, Neal, ML, Siedlak, SL, Smith MA, LaManna, J, Friedland, RP.  Aged YAC A β PP transgenic mice developed atherosclerotic lesions and mitochondrial DNA deletions in brain microvessels. Third World Congress on Vascular Factors in Alzheimer’s Disease, Kyoto, Japan, April 7-10, 2002.

229.  Friedland, FR, Bowirrat, A, Korczyn, AD.  Vascular Dementia among Elderly Arabs in Wadi Ara.  Regional North American Annual Meetings of the World Federation of Neurology – Research Group on Neuroepidemiology, Denver, Colorado, April 2002, Neuroepidemiology, 2002-21, pp.4-5 (Abstract), 2002.

230.  Bowirrat, A, Friedland, RP, Korczyn, AD.  Prevalence of age-related cognitive decline and incidence of Alzheimer’s disease in an elderly Arab population in Wadi, Ara, Israel.  Regional North American Annual Meetings of the World Federation of Neurology – Research Group on Neuroepidemiology, Denver, Colorado, April 2002, Neuroepidemiology, 2002-21, p. 5 (Abstract), 2002.

231. Korczyn, AD, Bowirrat A, Friedland, RP.  Mortality from dementia of Alzheimer type among Elderly Arabs in Wadi Ara.  Regional North American Annual Meetings of the World Federation of Neurology – Research Group on Neuroepidemiology, Denver, Colorado, April 2002, Neuroepidemiology, 2002;21, p. 5 (Abstract), 2002.

232. Mizrahi E, Jacobsen D, Petot G, Korczyn AD, Friedland RP. Plasma total homocysteine, vitamin B12 and folate levels in AD and healthy controls and Arabs residing in Israel. Forth Bessie and Louis Stein Geriatrics Conference in Advance of Rehabilitation in the Elderly, Tel Aviv, January 2003.

233. LaManna JC, Xu K, Puchowicz MA, Radhakrishan K, Seyidova D, Shi J, Aliev G, Friedland RP. Age-dependent features of cerebral blood flow change in APOE deficient mice.  Second International Conference on Cerebral Amyloid Angiopathy.  December 2002, Newcastle.

234. Petot GJ, Traore F, Debanne SM, Fritsch T, Lerner A, Friedland RP. Dietary patterns and antioxidant intake during mid-adult life as risk factors for Alzheimer’s disease. International Academy of Nutrition and Aging, Second International Meeting, Albuquerque, July, 2003.

235.  Shi J, Seyidova D, Perry G, Lamb BT, Lamanna JC, Friedland RP, Aliev G. Abnormal ultrastructural features of neuronal mitochondria in C57B6/SJL transgenic mice overexpressing amyloid beta precursor protein. American Academy of Neurology 55^th Annual Meeting, Honolulu, Neurology 60(S 5):A67, March 2003.

236.  Fritsch T, Smyth KA, Debanne SM, Vega U, Petot GJ, Lerner AJ, Friedland RP.  The relationships between novelty-seeking leisure activities and Alzheimer disease.  American Academy of Neurology 55^th Annual Meeting, Honolulu, Neurology 60(S 5):A129-130, March 2003.